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ABSTRACT 
 
DEVELOPMENT OF A SUBUNIT VACCINE AGAINST BOVINE DIARRHEA 
CAUSED BY K99 ENTEROTOXIGENIC ESCHERCHIA COLI AND BOVINE VIRAL 
DIARRHEA VIRUS 
EMAD HASHISH 
2013  
Bovine diarrhea is economically one of the most important problems in cattle 
industry. Enterotoxigenic Escherichia coli (ETEC), particularly strains expressing K99 
(F5) fimbriae and heat-stable type I (STa) enterotoxin is the predominant bacterial cause 
of diarrhea in calves; whereas bovine viral diarrhea virus (BVDV) causes diarrhea and 
other illness to cattle at all ages. A vaccine that prevents against both K99 fimbrial ETEC 
and BVDV could benefit greatly to cattle producers worldwide. We hypothesized that a 
novel multivalent vaccine composed of  K99, STa and BVDV E2 antigens could induce 
immunity for broad protection against bovine diarrhea. In this study we applied FanC, the 
major fimbrial subunit of K99, as a backbone to have a STa toxoid and the most 
immunogenic E2 epitopes embedded to construct ‘FanC-STa-E2’ fusion antigen, and 
examined this ‘FanC-STa-E2’ fusion antigen for immunity against ETEC and BVDV in a 
murine model for vaccine potential assessment. Adult female BALB/C mouse 
intraperitoneal (i.p.) immunized with 200 µg purified antigen with equal volume of 
adjuvant.  Developed systemic and mucosal immune responses to K99, STa, and BVDV 
E2.  Moreover, those antibodies showed abilities to block the E. coli K99 bacterial 
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adhesion  by K99-receptor positive INT-407 and IPEC-J1 cells, neutralized the STa 
enterotoxin, and also neutralized the BVDV infection. This suggests that this fusion 
antigen has the potential to be developed as a broadly protective vaccine against bovine 
diarrhea. 
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Chapter One 
Literature Review 
Introduction   
Diarrhea is not a specific disease but it is a symptom of many diseases, which 
might be the principal or secondary symptom. Diarrheal infection causes morbidity and 
mortality among animals, particularly young animals and results in significant economic 
losses [2]. Indeed, diarrhea is the most significant disease in neonatal dairy calves 
worldwide [3]. Calves within the first months of life are usually at a greatest risk of 
developing diarrhea, while the incidence of diarrhea decreases with increasing age [4, 5]. 
Neonatal calf diarrhea results in significant economic losses and increases production 
costs due to treatment, diagnosis, labor and the veterinary intervention [6].  Although 
infectious diarrheal diseases reflect interaction between pathogen and hosts, and also  
environmental and management factors, enteric pathogens play the major role in causing 
diarrhea. It is reported that enteric pathogens are found associated with around 97.6% of 
outbreaks and were detected in 95.0% of the fecal samples collected from dairy and beef 
calves with diarrhea in Australia [7].   
As ETEC is the predominant cause of calf diarrhea and BVDV is the main viral 
cause of diarrhea in cattle at all ages, the major focus in this study is on these two 
pathogens. ETEC strains cause severe watery diarrhea in calves and other young animals 
such as piglets [8]. BVDV can cause diarrhea and other illness, such as the widespread 
lesions in the gastrointestinal tract with diarrhea and respiratory symptoms, there is a 
severe form of BVDV called BVDV-mucosal disease complex (BVDV-MD) [9]. 
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Vaccination     
Vaccines prevent and control diseases in humans and animals.  The first recorded 
use of a vaccine by the ancient Greek king of Pontus, Mithridates VI. in 1st Century, BC.. 
He tried to protect himself from being poisoned through the repeated consumption of 
small amounts of poisonous substances in honey (theriaca) [10]. The first veterinary 
vaccine was Pasteur’s preparation to immunize chickens against fowl cholera [11].  
Vaccination is an important approach to prevent or prophylaxis of the disease, by 
providing good immunological responses before natural infection taken place, so that to 
reduce the cost of therapeutic approaches. Vaccination programs generally aimed to 
control infectious diseases in man and animals and also to reduce or to prevent the 
morbidity and mortality. Enteric diseases, however, remain endemic and largely have no 
effective vaccines available [12].  Vaccines are expected to induce specific antibodies 
directed against infections by specific pathogens to confer the protection [13].   
Traditional vaccines were attenuated either by serial passage of an agent in tissue 
culture or inactivation of an agent by chemical or physical means. But these vaccines 
have disadvantage including reversal to virulence in case of live attenuated vaccine that 
result in the production of disease. Genetic engineered vaccines through molecular 
biology, are thought to have great promise [14]. Different types of vaccines: killed whole 
cell bacterins, inactivated virus, live attenuated bacteria and viruses, and subunit 
including synthetic peptides and toxoid vaccines, are currently in use to control viral and 
bacterial infection [10, 15]. Subunit vaccines have become preferred over the live 
vaccine, because presents an antigen (protein or peptides) to the immune system without 
introducing pathological particles. The advantage of the Subunit vaccines is the 
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increasing in the safety concerns, less antigenic competition and selection of the most 
immunogenic peptides or protein which directly target and stimulate the immune system. 
However subunit vaccines require preparation and purification in a large volume and 
administered in appropriate confirmation to elicit desired immune responses [14]. Other 
approaches have also been attempted, including production of transgenic plants that 
produce edible antigenic proteins to induce immunity against pathogens including diverse 
enteric and non enteric pathogens [16]. This transgenic plant system has been 
demonstrated to express and produce foreign proteins that elicit specific immune 
responses in the murine system [17].   
Advances in molecular biology allow scientists to isolate virulence genes from 
pathogens and to express these genes in vectors and to vaccinate with this DNA [10, 14]. 
This recombinant genetic approach leads to a concept of multivalent vaccine. Multivalent 
vaccine concept was tried in developing multiepitope subunit vaccine to protect against 
extraintestinal pathogenic Escherichia coli [18]. A single multivalent vaccine can be used 
against different diseases. An example is the  multivalent DNA-based vaccine against 
rabies and canine distemper in mice and dogs[19]. In addition, like any traditional 
vaccines, a multivalent vaccine can be co-administrated with other vaccines 
simultaneously to provide broad protection. Co-administration reduces the number of 
injections that resulted in lowers vaccination cost [20]. However, before applying any 
vaccination program in a disease control program, careful consideration should be taken 
regarding political, practical, scientific and economic factors. Otherwise the wrong 
decision may result in waste of resources, the spread of disease, trade restrictions and the 
loss of public confidence [21]. The vaccine must be cost-effective to combat and 
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eradicate infectious diseases, as developing countries are typically endemic to infectious 
diseases [22].     
Escherichia coli    
Escherichia coli are gram negative rod shaped bacilli that typically colonize the 
gastrointestinal (GI) tract of humans and animals as a normal flora of the GI system. E. 
coli are mostly non-pathogenic, harmless bacteria and can be beneficial to the host by 
participating in vitamin metabolism [23] or by blocking establishment of enteropathogens 
through competing for limited nutrients or bacterial binding receptors [24]. They usually 
remain normal inhabitant in the intestinal lumen without producing any diseases. Only 
very limited number of  pathogenic E. coli strains cause clinical diseases such as urinary 
tract infection, diarrheal disease, and meningitis [25].    
Diarrheagenic E. coli strains are a group of the pathogenic E. coli causing 
diarrheal diseases in both humans and animals. Theses E. coli strains deliver toxins to 
host cells to cause fluid hyper-secretion in host epithelial cells to cause diarrhea. Once 
colonized, diarrheagenic E. coli strains exhibit remarkable versatility to cause diarrhea. 
Based on their virulence mechanisms, epidemiology and serotypes, six distinct groups 
were recognized: enteropathogenic E. coli (EPEC), enterohemorrhagic E. coli (EHEC), 
enteroaggregative E. coli (EAEC, enterotoxigenic E. coli (ETEC), enteroinvasive E. coli 
(EIEC), and diffusely adherent E. coli (DAEC) [25, 26].     
Enteropathogenic E. coli (EPEC) causes persistant watery diarrhea in children 
less than two years old in developing countries [27]. Enterohemorrhagic E. coli (EHEC) 
occurs in industrialized nations, where adults and children can suffer from either bloody 
or non-bloody diarrhea or hemolytic uremic syndrome with Shiga toxins (Stx) production 
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[25, 26]. Enteropathogenic and enterohemorrhagic E. coli (EPEC and EHEC) share 
several characteristics such as, locus of enterocyte effacement[28], pathogenicity island 
(PAI), encoding a type III secretion system [29], capability to form attaching and effacing 
(AE) intestinal lesions, and intimate attachment to the host cell [27, 30]. 
Enteroaggregative E. coli (EAEC) is responsible for travelers’ diarrhea in industrialized 
and developing countries characterized by aggregative adherence (AA) to HEp-2 cells in 
culture[31].  Enteroinvasive E. coli (EIEC) strains cause diarrheal disease and dysentery 
in young children in developing countries [31, 32] and food-borne outbreaks of enteric 
disease in adults in industrialized countries [33]. High fever, malaise, abdominal cramps, 
and overt dysentery are symptoms produced from the cytotoxins and enterotoxins 
involved in EIEC infection [34].   
ETEC is the major bacterial cause of diarrhea [26]. ETEC bacteria commonly 
cause colibacillosis in humans, pigs and calves, but less common in dogs and cats. 
Colibacillosis refers to adherence of bacteria to the microvilli of small intestinal epithelial 
cells but with no induction of any morphological lesions, and enterotoxic activity caused 
by produced enterotoxins which act locally on enterocytes to cause diarrhea. 
Colibacillosis among the neonatal pigs and calves is directly responsible for high 
economic losses [8]. Human ETEC is responsible for a high mortality rate of infants in 
the developing countries, also is considered as the most common cause of diarrhea among 
travelers from industrialized countries to the tropical or subtropical areas of the world 
[26, 35-37]. ETEC diarrhea starts with ingestion of contaminated food or water. Theses 
bacteria adhere to the small intestinal epithelial cells of the newborn or very young 
animals through the production of thin (3-7 nm) proteinaceous surface appendages  called 
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fimbriae or pili. Fimbriae are morphologically, biologically and antigenically different 
among various ETEC strains. Fimbriae ETEC bacteria colonized at the gut that allows 
bacteria to secrete enterotoxins to the target cells. That stimulates the small intestine for 
increased water and electrolyte secretion but prohibits fluid absorption, and leads to 
diarrhea [8].  
Two types of virulence factors are identified in ETEC infections, the adhesive 
fimbriae and secretion of enterotoxins. Fimbriae and enterotoxins are different among 
different ETEC strains. ETEC strains causing newborn calves diarrhea carry adhesins 
K99 (F5) and/or F41 and porcine-type STa (pSTa) enterotoxins [8, 38], that is different 
from ETEC strains associated with diarrhea in suckling piglets that express K88 (F4) 
adhesins (K88ab, K88ac and K88ad) [39], F18,  K99 (F5) or 987P (F6) adhesins [8] and 
occasionally F41 [40], F165 [41] or F42 adhesins [42].  The most common ETEC causing 
diarrhoea in pigs express K88 and LT and p STa or STb [8]. This study focuses on the 
K99 fimbrial ETEC strains that cause diarrhea in calves.  
E. coli Pathogenesis  
Two major virulence factors are associated with ETEC infection and 
pathogenesis. They are adhesions or fimbrial mediate ETEC colonization at host small 
intestine and enterotoxins including,   the heat-labile enterotoxin (LT) and/or heat-stable 
enterotoxin (ST) [8, 25, 26, 43]. Host specificity, mainly determined by the presence of 
specific receptors, effects outcomes of ETEC infections [8]. Colonized ETEC bacteria are 
able to elaborate the enterotoxins to host cell and fluid secretion that leads to diarrhea [8, 
25]. ETEC associated with animal diarrhea produce several important adhesions or 
different types of adhesions, such as the F4(K88), F5(K99), F6(987P), F41, F42, F165, 
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F17 and F18 fimbriae,  as well as different types of enterotoxins including, heat-labile 
(LT) and heat-stable (ST) enterotoxins which can be further classified in to LTh-I, LTp-I, 
LTlla, LTIIb, hSTa, pSTa, STb [8].  
A. Colonization factors    
Colonization of the host small intestine is a necessary prerequisite for ETEC to 
cause diarrheal disease. So that establishment of bacterial adherence to enterocytes is an 
important step to initiate ETEC infection and diarrhea. Colonization occurs by adhesion 
to the host mucosal surface [44, 45]. As stated before there are several types of fimbriae 
that are host specific. High species specificity of ETEC fimbriae has been discovered 
[36]. This adhesion is mediated by specific adhesins or fimbriae found on the outer 
surfaces of ETEC [46, 47].  Different colonization factors have been reported in human 
and animals, with more than twenty colonization factor antigens (CFA) in human ETEC 
strains and several fimbriae in animal ETEC strains that are responsible for the adhesion 
[48, 49]. Fimbriae are filamentous appendages on bacteria that allow colonization of host 
epithelial surfaces, that brings ETEC in close proximity to host cells and elaborates 
enterotoxins to epithelial cells [50, 51].  ETEC fimbrial adhesins mediate the attachment 
to the brush border of epithelial cells small intestinal microvilli, establishing colonization 
and resisting removal without inducing morphological lesions [8, 25].     
ETEC strains associated with diarrhea in calves and lambs express two fimbrial 
adhesins called K99 (F5) and F41 [52]. Small intestinal adhesion and colonization by 
ETEC is facilitated by the fimbria-receptor interaction, and the susceptibility of young 
animals to ETEC infections is determined by the presences of receptors specially 
recognized by ETEC adhesions [43]. The presence or absence of adhesin receptor genes 
8 
 
 
is responsible for the host specificity of ETEC infection regarding adhesion and 
colonisation which would be different in different animal species. K99 fimbriae are 
responsible for the attachment of the bacteria to the host epithelium cells and facilitate 
subsequent bacteria colonization [37]. The K99 fimbriae specific receptor is the small 
intestinal glycolipid ganglioside N-glycolyl-GM3 (NeuGc-GM3) that binds laterally at 
numerous positions to the fimbriae [53, 54]. On the other hand, the degree of expression 
of host receptor genes is influenced by age and reflects the resistance or the susceptibility 
to adhesion by ETEC. The glycolipid  receptors for F5(K99) [54] has been reported to be 
declined with increase of age of the animal [55]. The K99 fimbrial antigen was 
characterized as a single repeating protein subunit [56].  The major subunit called 
fimbrillin forms fimbrial structure and recognizes host receptor ganglioside [57]. The 
FanC has been reported as the major k99 fimbrial subunit act as adhesin at numerous 
positions along fimbriae and result in binding between the fimbriae and receptor , so that 
the adhesive properties is associated with the fimbriae [53].  
B. Enterotoxins 
Enterotoxins are plasmid-regulated exotoxins or extracellular proteins or peptides 
which are able to exert their actions on the intestinal epithelium [8]. After bacterial 
colonization to the small intestine using specific fimbriae, the ETEC is able to efficiently 
transmit the enterotoxins, which disrupt fluid homeostasis in intestinal epithelial cells, 
and result in functional change which lead to secretory diarrhea [8, 25]. ETEC has two 
major classes of enterotoxins, the large-molecular-weight heat labile toxin (LT) and the 
small-molecular weight heat stable toxin (ST), which are different in structure, function 
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and immunogenicity.  LT predominantly secreted by human and porcine ETEC strains, 
while ST usually produced by ETEC of human, porcine and bovine origin [8]. 
1- Heat labile toxin     
The heat labile toxin (LT) is very closely related to cholera toxin (CT) that is 
expressed by Vibrio cholera in function and structure [50, 58]. LT is a hexameric protein 
composed of a ring-shaped homopentameric B subunits of 11.5 kDa which strongly bind 
to its specific intestinal receptor (ganglioside GM1), and a single A subunit of 28 kDa 
which is responsible for the enzymatic activity of the toxin, and is proteolitically cleaved 
to yield A1 and A2 peptides joined by a disulfide bond [25]. The pentamer B subunits 
bind LT at host cell surface, then LT enters into the cell through an endocytic process. 
Heat-labile enterotoxins can be divided into two known categories, the LTI and LTII. LTI 
are expressed by ETEC associated with diarrhea in humans and animals, while LT-II, 
primarily found in animal E. coli isolates, has not been associated with disease [8]. 
Where LTI has two subclasses the LTh-I (human) and LTp-I (porcine), where LTII has 
two antigenic variants (LTIIa and LTIIb) [8].     
Adenylate cyclase (AC) is the cellular target of LT, located on the basolateral 
membrane of polarized intestinal epithelial cells [25]. After binding to ganglioside GM1 
receptors at the host epithelial cells through the B subunits, LT holotoxin is endocytosed 
and translocated into host cells [59]. The A1 fragments translocate into the cell and 
activate the adenylate-cyclase system through ADP-ribosylation of the alpha subunit of 
GTP binding protein Gs with the activation of the catalytic unit of cAMP dependent 
protein kinase, thereafter, adenylate cyclase is permanently activated by the ADP-
ribosylation of the GTP-binding protein, leading to increased production of intracellular 
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cyclic AMP [38]. cAMP phosphorylates the membrane proteins leading to transepithelial 
ion transport disorders and intracellular accumulation of cAMP which elicits secretion by 
crypt cells and decrease absorption by villus tip cells [8, 25]. As a result, hypersecretion 
of electrolytes and water into intestinal lumen occurs, and diarrheal disease is induced 
[60].  
2- Heat stable enterotoxins   
Heat stable enterotoxins (ST) are small monomeric proteins, classified into two 
classes, the STa and STb or STI and STII respectively. Two types of STa are recognized: 
the pST (ST porcine or STIa) and hST (ST human or STIb) [61]. STp and STh have a 
50% sequence homology, and they are identical in the 13 residues necessary and 
sufficient for enterotoxicity, six of them are cysteines which form three intramolecular 
disulfide bonds [8, 25]. The STa major receptor is membrane spanning enzyme belongs 
to the receptor cyclases family called guanylate cyclase C (GC-C) which located on the 
apical membrane of intestinal epithelial cells, where the ligands binding to the 
extracellular domain stimulates the intracellular enzymatic activity [61]. The GC-C 
receptor which spanned the cell membrane and composed of the extracellular binding 
domain (ECD), single small transmembrane domain, single transmembrane helix, the 
cytoplasmic intracellular protein kinase homology domain (KHD), catalytic domains and 
a carboxy-terminal domain [62, 63]. 
STa is synthesized as a 72 amino acid precursor proteins consisting of a pre signal 
peptide, a pro sequence, and the carboxy-terminal enterotoxin [64, 65], and synthesized 
as an intracellular pre-pro-STa polypeptide [66]. The amino acids 1-19 is considered a 
signal peptide that directs the translocation of the pre- pro-STa polypeptide across the 
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inner membrane [65]. Where the outer membrane translocation is accompanied by the 
cleavage of the  pre-pro-STa polypeptide into the mature peptides, where pSTa & hSTa 
have 18- or 19 mature amino-acid peptide respectively which are cleaved by a SecA-
dependent export pathway, and has  a molecular mass of ca. 2 kDa [66, 67]. The mature 
STa has three intramolecular disulfide bonds between six cysteines. 
The STa binding is followed by the stimulation of GC activity and increased 
intracellular cGMP levels [68-70], with the activation of cGMP-dependent kinases [70]. 
Then phosphorylation of the CFTR chloride channel leads to secretion of Cl
-
 ions into the 
intestinal lumen [8, 62]. It has been reported that the activation of cGMP-dependent 
protein kinase II (cGK II or PKG) is sufficient and necessary to activate Cl
-
 secretion 
[71]. The cGK II knock out mouse has been reported as not responsive to ST, guanylin, 
or cGMP [72]. Finally, the net outcome is the stimulation of guanylate-cylase system 
with intracellular accumulation of cGMP which induces a reduced absorption of water 
and electrolytes on villus tips with extensive excretion of Cl
- 
and water into the crypt 
cells, causing dehydration and diarrhea causing the stimulation of chloride secretion 
and/or inhibition of sodium chloride absorption, resulting in net intestinal fluid secretion 
[8].  
Since STa is a small molecule, it is not immunogenic in its natural form. Several 
approaches have been developed to enhance its immunogenicity as a vaccine target. One 
of the problems is that the actual amount of STa toxin produced by an ETEC strain 
during an ETEC infection in humans is unknown. Since STa is unable to produce anti-ST 
antibodies during natural ETEC infections, strategies must be developed to induce 
neutralizing anti-STa antibodies. It could be difficult to achieve complete ST 
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neutralization. Immunity may then depend on partial protection against the ST toxin to 
effectively reduce the ETEC disease burden and pathogenesis [67].   
Escherichia coli K99 fimbriae    
ETEC K99 fimbrial antigen is classified based on antigenic and genetic 
characteristic. Structurally, K99 is composed of fimbrillin that forms the main part of 
fimbriae and adhesin which recognizes carbohydrate receptors on the surface of host cells 
[54, 56]. Genetically, K99 ETEC fimbriae have eight different genes involved [73]. The 
genetic determinants for ETEC K99 fimbriae requires the in vivo biosynthesis of eight 
unique polypeptides genes named fanA, fanB, fanC, fanD, fanE, fanF, fanG, fanH [74]. 
Those genes reside on a large plasmid, encodes six structural genes clusters and eight 
subunits fanA-fanH [75]. Those subunits have been analyzed and the function has been 
determined. The full operon has been cloned [76, 77]. K99 is transmissible, being 
genetically encoded on an 87.8-kb plasmid [1]. Organization of this Fan operon is 
complex, and is regulated at the transcriptional level by a variety of factors [73, 78]. 
Several factors affect the expression of K99, it has been shown to be dependent upon 
cyclic AMP (cAMP) [79], cAMP receptor protein (CRP) [74, 80], and leucine-responsive 
protein (LRP) [81].  
The K99 operon composed of three separately regulated gene clusters: region I, 
encoding fanA to fanD; region II, encoding fanE and fanF; and region III, encoding fanG 
and fanH [74]. The expression of region I is not dependent on region II or III, as the fanC 
expression was not altered when region II and III genes were removed [73]. Two open 
reading frames located upstream of FanC gene are named as FanA with a molecular mass 
of 11.000 daltons and FanB with a molecular mass of 10.500 daltons, and these two 
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genes served as a regulatory elements which control the expression of K99 fimbriae [82]. 
A region with dyad symmetry within FanA supposed to represent the cis-acting element 
and allow the FanA and FanB to interact with the termination factors preventing the 
termination at T1 and T2 [83].  
FanC is the most highly expressed protein in the Fan operon [73], the major 
structural subunit and immunogenic polypeptide of K99 fimbriae [84]. It encodes 181 
amino acid precursor protein [85], with a molecular weight of 18.500 daltons [85, 86], 
those amino acid residues composed of a single repeating protein [73, 86]. FanD served as a 
platform protein presumed to be an usher, and  codes for a polypeptide of 783 amino acid 
residues with a molecular mass of 84549 daltons for the mature FanD protein, and 
showed a significant sequence homology with FaeD, the large outer membrane protein 
encoded by the K88 operon [87].  FanE starts with GTG (valine) as starting codon which 
overlapped by fanD stop codon and composed of 207 amino acids and 3 restriction 
enzyme sites HincH, CiaI and AvaI, while fanF with starting region overlapped by the 
terminal region of fanE, consisted of 251 amino acids with a 2 restriction enzyme sites 
Sau3AI and XmnI[57].  With a molecular mass of 22.9 and 31.5 kilodaltons for fanE and 
fanF respectively[82]. The FanF encode 333 amino acids[88] with two open reading frames 
reported, 999 bp [89] and 813 bp [57]. On the basis of DNA sequence homology, FanE is 
presumed to be a chaperone [90], FanF to FanH encode minor subunits are believed to be 
involved in pilus assembly and elongation [89].  
Vaccines against K99 fimbrial ETEC    
Since ETEC fimbriae are major colonizing factors in ETEC-associated diarrhea, 
studies focus on ETEC fimbriae as the primary target for vaccination against ETEC [91]. 
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Early studies used purified Escherichia coli K99 pili as well as Formalin-killed whole 
cell bacterin as a vaccine against enterotoxigenic colibacillosis in suckling calves and 
piglets, This vaccine was safe and effective against K99 [92]. Other studies were 
conducted to examine the protecting effect on newborn calves born through vaccination 
of pregnant cows and heifers with the crude K99 extract prepared from an Escherichia 
coli K-12, K99 strain. Anti-K99 colostral antibodies were detected in the vaccinated 
group. Calves born by the vaccinated cows, when challenged orally with enterotoxic E. 
coli B41 (0101:K99+, ST+) at the time of first colostrum uptake, had no death occurred. 
In contrast all calves in the control group died [93].     
K99 antigens were attempted to be expressed in plants as an edible vaccine 
candidate. The major K99 fimbrial subunit used as an edible subunit vaccine, where 
cytosol targeting with a synthetic version of FanC in soybean was developed and the 
extracted protein from the transgenic leaves develop a high antibody titer in mice [84]. 
Subcellular targeting of FanC to chloroplasts as edible transgenic plants was developed, 
but did not reach their full potential as a renewable source of oral vaccines [94].    
Recently some researcher started to use a mucosal delivery system trying to elicit 
a better systemic and mucosal immune response. One group constructed a balanced lethal 
stabilized asd+ plasmid carrying the complete K99 operon, introduced into an attenuated 
Salmonella typhimurium to expresses E. coli K99 fimbriae, and found K99 fimbriae were 
effectively delivered to mucosal inductive sites for sustained elevation of IgA and IgG 
antibodies and for induction of protective [95]. Another group used a recombinant fusion 
proteins of pgsA and fimbriae protein of ETEC K99 to expose the fusion proteins on the 
surface of non-pathogenic strain Lactobaccilus casei, orally and  intranasally  immunized 
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BALB/c mice. They found immunized mice developed both systemic and mucosal 
immune responses, with high levels of serum immunoglobulin G and mucosal IgA 
against ETEC K99 [37].  It was also reported that a vaccine used Lactobacillus casei as a 
mucosal delivery to express K99 or K88 elicited high levels of mucosal IgA titers in 
mouse bronchoalveolar lavage fluids, intestinal fluids and prominent systemic IgG 
subclasses (IgG1, IgG2b, and IgG2a) responses in sera [96].     
Bovine viral diarrhea virus  
Viruses have two different strategies to produce infection. They can produce a 
persistent infection in individual animals or they use a hit and run strategy with a short 
duration of infection and rapid transfer to the next host [97]. Bovine viral diarrhea virus 
(BVDV) is one of the most important pathogens of cattle [9].  It causes significant 
economic losses worldwide. BVDV uses a persistent infection strategy to produce 
infection. It was first recognized in the United States in association with outbreaks of 
acute and fatal disease charterizied by diarrhea, high mortality rate and erosive lesions of 
the digestive tract [98, 99]. It infects domestic and wild ruminants worldwide [100]. 
BVDV infections ranged from clinically in apparent to severe disease involving one or 
more organ systems [99]. BVDV is a small positive stranded RNA virus. It belongs to the 
Falviviridae family and pestivirus group. It has two genotypes, the BVDV1 and BVDV2. 
BVDV is also unique in that in cell culture it exhibits two different biotypes, non-
cytopathic (ncp) or cytopathic (cp) strains [100].   
The ncp biotype of BVDV infections has the biggest impact on cattle during the 
breeding season or pregnancy[101]. If the infection occurs early in gestation (40-120 
days of gestation) before the adaptive immune system matures, the ncp BVDV may 
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establish persistant infected animal (PI). The fetus may be born healthy but remains 
infected for life, and also remains immunotolerant to BVDV and remains a reservoir of 
the virus that can then infect healthy animals [9, 102]. Mucosal disease (MD) occurs 
when the PI animals acquire an infection with the cp-BVDV biotype, the combination of 
cp and non cp BVDV strains causes a MD form of BVDV, characterized by the 
widespread lesions in the gastrointestinal tract with diarrhea and respiratory symptoms 
[9].    
BVDV genome 
The BVDV has a positive single stranded RNA genome. It has a single ORF that 
is divided into different viral proteins, the structural and non structural proteins. The 
structural proteins are located at the 5ˋ end, the non-structural proteins are located on the 
3ˋ end of the genome [9]. Four official species of genus Pestivirus have been identified, 
include BVDV-1, BVDV-2, classical swine fever (CSF) and border disease virus (BDV) 
[103]. BVDV1 and BVDV2 are two BVDV genotypes with non-cytopathic (ncp) and 
cytopathic (cp) biotypes [100]. The ncp strains are more common than the cp strains and 
the BVDV-1 genotype is more common than BVDV-2 genotype [104]. The cp  BVDV 
is able to produce a morphological changes in the tissue culture including vacuolation 
and cell death while the ncp is not producing any morphological changes in the tissue 
culture [102]. BVDV ORF encodes the following proteins from 5’ to 3’. NH2-N
pro
-
capsid-E
rns
-E1-E2-P7-NS2-NS3-NS4a-NS4b-NS5a-NS5b-COOH [105, 106], this,  single 
polyprotein is post-transitionally processed to produce the mature structural and non-
structural proteins [107].  
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The structural proteins (capsid-E
rns
-E1-E2) are incorporated into the virus 
structure or particle. The capsid or core protein encapsulate or coat and protect the 
genomic RNA[106]. The E
rns 
protein is a heavy glycosylated protein, while E1 and E2 are 
integral membrane protein [106]. A major part of humoral immune response and strongly 
neutralizing antibodies were identified against E2 glycoprotein, where the major 
antigenic determinants and the major part of the humoral immune response is directed to 
the N-terminus of the E2 glycoprotein [107-110]. That is why it is important to include 
the E2 glycoprotein in a BVDV vaccine.  The 6 non-structural proteins are located in last 
two-thirds of the ORF and are involved in the viral replication[102]. N
pro
, a non-structural 
and unique protein for pestiviruses, is an autoprotease, which sometimes cleaves the 
polyprotien after translation[106].  it blocks the interferone production by directing IRF3 
(the interferon inducer in viral infected cells) proeosomal degradation [97]. The cleavage 
of NS2/3 is responsible for the production of cp effect in tissue culture, where the 
persistent infected immunocompetent animal combined with cp BVDV can develop 
mucosal disease [102].  
BVDV vaccine  
The glycoprotein E2, the most immunogenic protein of BVDV and elicits high 
titers of neutralizing antibodies after infection [110]. The virus transmission is blocked in 
the presence of neutralizing antibodies. Therefore, E2 constitutes an excellent antigen for 
vaccine candidates [111]. E2 protein of BVDV can be expressed with different 
expression systems. One study expressed the glycoprotein E2 subunit vaccine in the 
baculovirus expression system, and reported a prevention of transplacental transmission 
of virus beside protection of sheep fetus against homologous challenge [112]. Another 
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study used the baculovirus expression system for the production of a E2 glycoprotein 
vaccine or a vaccine that contained the structural polyproteins E0, E1, and E2 of BVDV. 
Both vaccines induced a solid humoral neutralizing immunity without complete 
protection in cattle [113].    
Another group expressed the E2 protein of bovine viral diarrhea virus (BVDV) in 
fowlpox virus (rFPV/E2) and then immunized mice. The mice demonstrated both BVDV-
specific humoral and cellular immune responses and the antibodies were able to 
neutralize BVDV [114]. Another group used three replication defective recombinant 
adenoviruses expressing the BVDV/E2. All three recombinant adenoviruses induced very 
strong BVDV specific antibody responses in a mouse model and produced a neutralizing 
antibody [115]. Another approach was to increase the E2 secretion [116] by intradermally 
immunizing mice with plasmid DNA encoding a truncated, secreted form of the BVDV 
E2 protein using four plasmids (pMASIA-gDsΔE2, pMASIA-tPAsΔE2, pSLKIA-
gDsΔE2 and pSLKIA-tPAsΔE2).  The pMASIA-tPAs_E2 elicited the strongest humoral 
and cellular immune responses and was identified as a candidate BVDV DNA vaccine.  
Epitope vaccines   
Epitope-based vaccine is an important approach to improve the immune response 
by isolation or optimization of specific components to induce the immune response 
against the pathogen [117]. In case of intracellular pathogens, as viral infection, it is 
important to identify putative T-cell epitopes through bioinformatics tools. The T cell 
epitopes play a role in the recognition and subsequent elimination of intracellular 
pathogens and improve the vaccine efficacy. Generally, epitope is the antigenic 
determinant or it is part of a macromolecule that is recognized by the immune system, 
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specifically by antibodies, or B or T cells. Computer based algorithms can detect 
antigenic peptide domains of a given protein which are likely to induce cellular immune 
response [118].  
Previously described ETEC and BVDV vaccines based on the entire pathogen 
organism, or proteins. While the epitope vaccines induce protective immune using 
selective epitopes without a risk of induction of the disease. So that an epitope based 
vaccine is safe, which is able to stimulate an effective specific immune response and 
avoid undesirable effects. It is composed of MHC-I and/or MHC-II epitopes which are 
required for stimulation of an effective immune response. There might be some limitation 
due to the use of small molecules which might be low immunogenic, so that the coupling 
with another protein using recombinant DNA technology or the administration of an 
appropriate adjuvant could enhance immunogenicity of epitopes.  
There are over 150 licensed biological products for BVDV control in United 
States, but none of them conclusively identified to stimulate a protective immune 
response against BVDV [119]. Identification of epitopes on a putative viral envelope 
glycoprotein, gp53 could be a good approach for BVDV control through viral 
neutralization. Neutralizing antibodies are considered an effective line of defense as they 
can intercept a virus before it attaches to its target cell and, thus, inactivate it [120]. 
Although there is no epitope vaccines developed for commercial use, several studies 
targeting specific immunogenic epitopes in vaccine design showed promising results for 
disease control. This might be considered an alternative approach for vaccine 
development. It was reported that an epitope based broad-spectrum influenza vaccine, 
which included epitopes from a majority of influenza virus strains, activated both the 
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humoral and cellular immune response [121]. Another study showed that a vaccine 
composed of CD4
+
 T cell epitopes from H. pylori adhesin A (HpaA), urease B (UreB) 
and cytotoxin-associated gene A product (CagA) with Th1 adjuvants elicited strong local 
and systemic Th1-biased immune response against H. pylori in a mouse model [122]. In 
the influenza virus vaccine, two surface protein antigens, the hemagglutinin and 
neuraminidase, were considered to be included in the vaccine [15]. Here, we designed a 
multiepitope vaccine which consists of K99 FanC, a pSTa toxoid, E2 B and T-cell 
epitopes for a broad protection against ETEC and BVDV.  
Objectives of the study  
The enterotoxigenic Escherichia coli (ETEC) strains expressing K99 (F5) 
fimbriae are the major cause of diarrhea in calves. The bovine viral diarrhea virus 
(BVDV) affects cattle of all ages. The K99 and BVDV can infect young calves causing 
severe diarrheal disease and huge economic losses. Particularly, it is makes sense to use a 
vaccine to protect calve against both pathogens and might also cattle at other ages. 
Previous vaccine candidates against Escherichia coli K99 consisted of single protein 
targeting FanC the major K99 subunit or the whole cell bacterin. Most of the bovine viral 
diarrhea vaccines were directed against E2 glycoprotien. No previous study combines 
K99 and BVDV in a single vaccine for providing a protection against both pathogens.  
 A vaccine for protection against both ETEC & BVDV infections has not been 
developed. A vaccine candidate based on K99 fimbria might be a good approach. K99 
colonization and the STa enterotoxin are the major virulence attribute of bovine ETEC. 
The E2 glycoprotein has a major role in BVDV entry and attachment in cattle. We 
decided to use a novel approach to include some epitopes against those virulence factors. 
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Free online software was used to detect B and T-cell epitopes of BVDV to be embeded to 
the K99 major fimbriae, fanC. The pSTa12 toxoid also included. It is well known that B-
cell epitopes play an important role in vaccine design. We select our BVDV B cell 
epitope from E2, where the amino acid sequence 71–74 considered immunodominant 
region and contain the common neutralizing epitopes on the BVDV-E2 (gp53) protein 
[108, 124]. 
Our research objective on chapter two was to construct a novel subunit vaccine 
candidate for the prevention of bovine pathogenic E. coli & BVDV infections in a murine 
model. FanC would be used as a backbone, and the pSTa toxoid and the E2 B and T-cell 
epitopes would be embedded in to FanC. This fusion antigen would provide anti-
adhesion, anti-toxin, and anti-BVDV immunity, and potentially to be developed as a 
subunit vaccine against K99 ETEC and BVDV in cattle.  
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Chapter Two 
Immunogenicity study of a novel chimeric fanC subunit antigen with embedded pSTa 
toxoid of enterotoxigenic Escherichia coli (ETEC) and BVDV E2 B and T cell epitopes 
of bovine viral diarrhea virus (BVDV) 
 Abstract 
Diarrhea is the most important problems in cattle. Enterotoxigenic Escherichia 
coli (ETEC) strains expressing K99 (F5) fimbriae and heat-stable type I (STa) 
enterotoxin are the major cause of diarrhea in calves, while the bovine viral diarrhea virus 
(BVDV) is the major cause of diarrhea in all ages of cattle. However, there is no single 
vaccine combined those two diseases. The conventional vaccines, including a single 
antigen from either fimbriae or enterotoxins, are not effective. It is important to develop a 
prevention strategy that can protect against diarrhea in calves.  The goal of the work 
presented here was to create a multivalent vaccine that protects calves against both 
pathogens. The K99 adhesin and STa enterotoxin are the major virulence determinants 
for ETEC, while the E2 glycoprotein is the most immunogenic protein of BVDV. We 
hypothesized that a novel multivalent vaccine consisting of FanC, the major fimbrial 
subunit of K99, STa and BVDV E2 antigens will induce broad protective immunity. We 
constructed a genetic fusion protein using the K99 major subunit FanC as a carrier of 
STa, B-cell and T-cell epitopes of the BVDV E2 glycoprotein (with STa & BVDV 
epitopes were embedded in the FanC major subunit). FanC exposed non conserved 
epitopes was  replaced by STa and BVDV E2 epitopes. This fusion protein was tested in 
a murine model for safety,  immunogenicity and to examine vaccine potency. Expression 
of the chimeric K99 FanC fimbriae, STa and BVDV-E2 antigens in these constructs was 
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expressed in a non-pathogenic E. coli strain and purified to be used in our study. Female 
BALB/C mouse 42-49 days immunized intraperitoneal (i.p.) with 200 µg purified fusion 
protein in an equal volume of adjuvant. The immunized mice developed strong humoral 
immune responses, anti-K99, anti-STa, and anti-BVDV antibodies. The antibodies from 
mouse sera samples were able to block ETEC K99 strain adhesion to INT-407 and IPEC-
J1 cells on a bacteria adherence blocking assay. Anti-STa antibodies were protective in 
vitro in cyclic GMP EIA as they could reduce the toxicity of STa toxin to T84 cells. Anti-
BVDV antibodies were able to prevent the BVDV NADL starin cytopathic effect in 
MDBK cells. This suggested that the K99 FanC fimbria can be served as a platform to 
express enterotoxin and BVDV antigens to induce protective antibodies. Besides, the 
novel fusion can be an ideal antigen for providing a broadly protective vaccine against 
diarrhea in cattle.  
 Introduction 
Diarrhea cause large economic losses especially among young animals, it might 
be a principal or secondary symptom of different diseases [2]. Enterotoxigenic 
Escherichia coli (ETEC) is the major bacterial enteric diseases causing diarrhea in calves 
[8]. Meanwhile, bovine viral diarrhea virus (BVDV) consider the major problems causing 
diarrhea in calves as it leads to widespread lesions in the gastrointestinal tract and 
development of mucosal disease [9]. Two major virulence factors should be included in 
ETEC infection and pathogenesis, the adhesions or fimbrial colonization to the small 
intestine and secretion of the enterotoxins. STa is the major enterotoxin secreted by K99 
ETEC causing diarrhea. E2 glycoprotein has a major role in BVDV entry and attachment 
in cattle plus the production of neutralizing antibodies, so that two E2 epitopes included 
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in our antigen (B and T-cell epitopes) from the E2 glycoprotein. No standard vaccine 
providing a protection against ETEC & BVDV was developed in a single product. So that 
any effective vaccine against bovine ETEC, including the major virulence factors with E2 
glycoprotein, is suspected to provide a protection against ETEC and BVDV. In this study, 
the non conserved exposed epitopes of the FanC major subunit was replaced by the three 
selected epitopes, the pSTa, E2 B-cell & T-cell epitopes to express fanC, STa and E2 
antigen in a single protein. The safety and immunogenicity of our antigen was tested in 
murine model and showed that our antigen can be used for potential application and 
vaccine development against bovine diarrhea caused by ETEC and BVDV. 
 
Materials and Methods: 
Bacterial strains and plasmids:  The plasmid K99, which contains the entire K99 
fimbrial gene cluster (FanA to FanH) [1, 73] in pBR322, was provided as a gift from Dr. 
R. E. Isaacson, at the Veterinary and Biomedical Sciences Department, University of 
Minnesota, Minnesota, USA [1]. This 1297 strain which carries the K99 operon (figure 1) 
was used for fimbrial chimera construction and pK99 fimbrial extraction (figure 2). 
Different primers were used for the construction of chimeric FanC (the major structural- 
subunit) of K99 fimbria. All strains and plasmids used in our study are listed in (table 3). 
Plasmid pET28a (Novagen) was used to clone and express the recombinant FanC gene 
with the embedded pSTa12, BVDV E2 B and T cell epitopes. Plasmid pMAL-p5X (New 
England Biolabs) was used to clone the BVDV-E2 gene for production of MBP (maltose 
binding protein)- E2 fusion as coating antigens for detection of BVDV antibodies using 
ELISAs. 
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Fig.1. Illustration of K99 fanC operon in recombinant E. coli strain 1297. Restriction 
mapping, size of various genes are shown in the diagram [1]. 
Fig.2. Gel electrophoresis of the K99 plasmid. pK99 extraction in 
1% agarose gel with 1kb marker. The expected size of the pK99 
plasmid is 11.5 kDa.  
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Prediction of FanC non conserved exposed peptide domains:  
The ConSurf server software was used for identification of antigenic regions in the 
protein. This program was used to detect the FanC for non-conserved but surface-
exposed epitopes http://consurf.tau.ac.il/ [125, 126].  These predicated epitopes were the 
targets to be replaced with pSTa12 and BVDV-E2 epitopes. The conserved and the most 
antigenic epitopes were retained for induction of anti-K99 immunity (figure 3).  
Inserted toxoid STap12F and two BVDV epitopes:   
Porcine Escherichia coli STap12F toxoid was inserted in FanC for the FanC-STa 
chimeria. The selected pSTa12 has a mutation in Pro12. Previous studies showed that 
Pro12 mutation is similar to other STa mutants showing a reduction in STa toxicity [127, 
128]. The inserted STap12F sequence is (NTFYCCELCCNFACAGC). Since B-cell 
epitopes plays an important role in vaccine design and the T cell epitopes plays an 
important role in controlling the viral infection, two E2 epitopes from BVDV type-1 
NADL strain envelope glycoprotein E2 were included: the most antigenic B-cell epitope 
and the most antigenic T cell epitope. Prediction analysis showed that the peptide 71–74 
represented an immunodominant region and a common neutralizing epitopes on the 
BVDV-E2 (gp53) protein [108, 124]. The BVDV E2 B-cell epitope was encoded from 
nucleotides, cat aca aga gcc ttg ccg acc agt gtg gta ttc which translated to11 amino 
acids(
70
HTRALPTSVVF
80
). T-cell epitopes were predicted based on MHC class I 
predication. The BVDV E2 T cell epitope was  drived from nucleotide fragment, gac caa 
cta cta tac aaa ggg ggc tct which translated to 9 amino acids (
193
DQLLYKGGS
201
).  
Amino acid residues 886 and 888 of the E2 T cell epitope (underlined),  were reported as 
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positively selected sites of BVDV type1 on the E2 gene [129]. All epitopes were 
confirmed using epitope selection software.   
 
 
Fig.3. Predication of antigenic regions in FanC protein (the K99 major subunit) which 
composed of 181 amino acids. Detected non conserved exposed amino acids were 
replaced with pSTa12 and BVDV E2 epitopes. 
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Epitope prediction with computer-based programs:  
Different software was used to predict BVDV E2 B and T cell epitopes. BVDV-NADL 
E2 glycoprotein amino acid sequence (accession NP_040937.1) was directly used in 
bioinformatics prediction software, then selection of the most common epitopes that have 
been repeated in different software. http://tools.immuneepitope.org/main/index.html 
[130], http://imtech.res.in/raghava//abcpred/index.html [131] 
http://ailab.cs.iastate.edu/bcpred/index.html [132] and 
http://www.imtech.res.in/cgibin/propred1/propred1.pl [133].  
Construction of the FanC chimeric gene:     
The FanC gene was amplified in PCR with pK99 plasmid as DNA template and 
specifically designed PCR primers (table.1). ConSurf software predicated peptides 91-
107, 116-126 and 154-162 of FanC as surfaced-exposed but less antigenic. These three 
fragments were removed through different PCR reactions and replaced with the 
Escherichia coli pSTa12 toxoid, and E2 B and T cell epitopes respectively using different 
primers (table 1). Splice overlapping extension (SOE) PCR was used to construct the 
chimeric FanC .PCRs were performed with a PTC-100 thermal cycler (Bio-Rad, 
Hercules, CA) in a 50µl reaction mixture containing 1X Pfu DNA polymerase buffer 
(with Mg2
+
), 200 nM deoxynucleoside triphosphate (dNTP), forward and reverse primers 
at 0.5 µM each, and 1 U Pfu DNA polymerase (Stratagene, La Jolla, CA). SOE PCR was 
performed in a reaction mixture containing 1X Pfu DNA polymerase buffer (with Mg2
+
), 
200 nM dNTP, 20µl each of the 5ˋ- and 3ˋ- end purified PCR products, 1 U of Pfu 
polymerase, and 0.5 U Taq DNA polymerase (Applied Biosystems, Foster City, CA).  
Amplified products were separated by 1-1.5% agarose (FMC Bioproducts, Rockland, 
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MA) gel electrophoresis and purified using a QIAquick Gel Extraction Kit by following 
the manufacturer’s instruction (QIAGEN, Valencia, CA).  
Cloning and expression of the chimeric gene:  
Amplified FanC chimeric gene product was digested with the unique restriction 
enzymes and the cloning vector was digested with the same enzymes. Restriction 
mapping software http://tools.neb.com/NEBcutter2/ was used for selection of the unique 
restriction sites. The purified PCR products and expression vector  pET28a were digested 
with Nhe1 and EagI restriction enzymes (New England Biolab, Ipswich, MA) 
respectively.  Two microliters of ligation products were used for transformation of E. coli 
BL21 competent cells under a standard procedures [134]. The digested gene products and 
vectors were purified and then ligated with T4 DNA ligase (New England BioLab). Two 
microliters of T4 ligated products were introduced to competent cells by electroporation. 
Positive colonies were initially screened by PCR then sequenced to ensure that the cloned 
genes were inserted in reading frame. The positive colony was selected for protein 
expression (figure 4). 
Preparation of the 6×His-tagged chimeric protein:     
Positive transformed cells grew in Luria Broth (LB) overnight at 37ºC in the presence 
of kanamycin, to an optical density at 600 nm (OD600) of 0.5, then pET28a recombinant 
vector were induced using 1mM isopropyl-ß-D-thiogalactopyranoside (IPTG) for an 
additional 4 h of culture. Inclusion bodies (IBs) were isolated using BugBuster Reagent 
BBR (Novagen) following the manufacturer’s instructions. Simply, the overnight grown 
culture was centrifuged  5000 Xg for 10 minutes at 4°C, pellets were collected for total 
protein preparation using B-PER reagent (in phosphate buffer) (Pierce, Rockford, IL).  
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The pellet was dissolved in B-PER, by vortex or pipeting up and down, then centrifuged 
15000 Xg for 15 minutes at 4°C. The supernatant was collected and labeled as soluble 
protein. The pellet was resuspended with 1:10 diluted B-PER in PBS then mixed with 
lysozyme 10mg/ml in B-PER then centrifuged 15000 Xg for 15 minutes at 4°C. Finally 
the pellet was resuspended two more time with diluted B-PER in PBS and the inclusion 
bodies were collected in PBS. 
Extraction and refolding of fusion protein:   
Purification of the inclusion bodies was done through Ni-NTA Beads for our 6x his-
tagged protein. The beads were washed; the protein was eluted in small volumes of buffer 
and confirmed by Western blotting and Coomassie blue staining. Dialysis of the purified 
protein against PBS overnight at 4°C. Extracted inclusion bodies were refolded using a 
Novagen refolding kit (Merck KGaA, Darmstadt, Germany). Briefly, the sample was 
collected from the overnight dialysis in PBS and spin at 4200 rpm at 4°C for 30 minutes, 
then the solubilization buffer was added to the pellet and dissolved gently by gentle 
mixing or pipeting up and down. The solubilized protein was refolded by the dialysis of 
the protein against refolding buffer. In summary, the fusion protein extracted in the 
format of inclusion bodies, solubilized and refolded before being used in mouse 
immunization.  
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Table.1:   
PCR primers designed to construct chimeric fanC gene. Underlined nucleotide represents 
the restriction enzyme sites, italic nucleotides are the inserted epitopes.  
  Primer                                     Sequence (5ˋ- 3ˋ) 
FanC-NheI-F2                  5ˋ-ATGATGGCTAGCACACTCCTAGCTATTATCTTAGGT -3ˋ 
FanC-EagI-R                    5ˋ-TCATCGATACGGCCGCAATGTAA-3ˋ 
STa12-fanC91-F   
5ˋ- GAACTTTGTAATTTTGCCTGTGCTGGATGTGGAAATACTGCTGCTAAAGGATACCAT-3ˋ 
STa12-fanC91-R   
5ˋ-GGCAAAATTACAACAAAGTTCACAGCAGTAAAATGTGTTGTTAGACCAGTCAATACGAGC-3ˋ 
BVDV-fanC116-F   
5ˋ-GCCTTGCCGACCAGTGTGGTATTCGCTAATATTAATACTTCATTCACTACG-3ˋ 
BVDV-fanC116-R   
5ˋ-ACTGGTCGGCAAGGCTCTTGTATGCAAAGTCATATGGTATCCTTTAGCAGC-3ˋ 
BVDV-fanC154-F             
5ˋ-CTACTATACAAAGGGGGCTCTGGTGGATATAAAGCTGGCGTATT-3ˋ 
BVDV-fanC154-R     
5ˋ-GCCCCCTTTGTATAGTAGTTGGTCCAGCTGGGCTGAATAGTTAAATGACT-3ˋ 
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Fig.4. Scheme of construction of chimeric FanC-STa-E2 protein. Arrows represent the 
primers used to insert STa and E2 epitopes. Transformation in E coli BL21 competent 
cell & the protein was extracted and purified.  
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Detection of fusion protein by SDS-PAGE& Western blotting:    
Protein was examined by Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blotting. The proteins were separated according to the 
molecular weight and visualized. Thirty microliters of prepared proteins were used for 
detection of the target protein in a standard SDS-PAGE and immunoblot assay method. 
After electrophoresis, gels were either stained with Coomassie blue or transferred to a 
nitrocellulose membrane. The blot was blocked with 0.5% milk in PBST /1 hr at RT. The 
membrane was incubated with one of these antibodies: anti-K99 (1:1000), anti-STa 
(1:2500) or anti-BVDV antibodies (1:1000). The blotted membrane was overnight 
incubated at 4°C of with the primary antibody. Multiple antibodies were used to ensure 
that the fusion proteins with the STa and E2 embedded epitopes. Membrane was washed 
with PBST three times and incubated with secondary antibody (HRP)-conjugated goat 
anti-mouse IgG (1:2500) or IgA (1:1000) for 1 hr at RT. After this, it washed with PBST 
three times and PBS once. The bloated protein was examined and detected on Odyssey 
Infrared Imaging System (figure 5).  
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Fig.5. Detection & characterization of the FanC-STa-E2 fusion protein. (A)Coomassie 
blue staining in SDS 12% polyacralymide gel. (B)Western blotting detection of the 
fusion protein using one of these: anti-K99 polyclonal antibodies 1:1000, anti-STa 
monoclonal antibodies 1:2500 or anti-BVDV-NADL strain polyclonal antibodies 1:1000. 
Band with a molecular mass of 22.5 kDa 
(A) (B) 
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K99 fimbrial extraction:    
E. coli K99 fimbriae were heat extracted based on a described method  [135]. The 
technique was similar to the one used to isolate K88 fimbriae but with some 
modification. Briefly, Escherichia coli K99 was grown on fresh sheep blood agar for 18 h 
at 37 °C and harvested in PBS. Harvested bacteria were suspended in PBS, and bacterial 
suspension was gently shaked at 65 °C for 40 minutes. While it still warm, the mixture 
was poured into a blender and blended for 2-3 minutes. Bacteria debris were removed by 
centrifugation 15000 xg  for 30 minutes. The supernatant was poured into a dialysis tube 
and kept overnight at 4°C. The pH of the supernatant fluid was adjusted to 4.0 by using 
dilute acetic acid 2.5% with continuous stirring for 10 minutes at 4°C or on ice. Crude 
antigen was found on the supernatant and Western blot analysis was confirmed the K99 
fimbrial protein using anti-K99 polyclonal antibodies 1:1000 (figure 6). Lawry protein 
assay, measures the protein concentration.  The purified fimbrial antigen 500ng was used 
as a coating antigen for ELISA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6. Western blotting detection of K99 fimbrial major subunit FanC 
using anti-K99 polyclonal antibodies 1:1000.  
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Construction of BVDV-E2 antigen  
BVDV-E2 antigen construction was described (figure 7). Plasmid pMAL-p5X 
(New England Biolabs) was used to clone the BVDV-E2 gene for MBP-E2 fusion 
protein. This protein was used as the coating antigen for detection of BVDV antibodies, 
from the animal study, by using the ELISA technique. Amplification of the BVDV E2 
glycoprotein gene was done in a RT-PCR reaction using different forward and reverse 
primers for each construct, including the unique restriction sites listed in (table.2). RT-
PCR rcreation is used to qualitatively detect gene expression through creation of 
complementary DNA (cDNA) transcripts from RNA. Amplified E2 gene product was 
digested with unique restriction enzymes detected by the restriction mapping software 
http://tools.neb.com/NEBcutter2/. DNA fragment of purified PCR products and plasmid 
pMAL-p5X were digested with Nde1 and BamH1 restriction enzymes (New England 
Biolab, Ipswich, MA).  Two microliters of ligation products were used for transformation 
into a non pathogenic E. coli BL21 competent cells under a standard procedures [134]. 
Digested gene products and pMAL-p5X vector were purified and ligated with T4 DNA 
ligase (New England BioLab). Two microliters of T4 ligated products were introduced to 
competent cells by electroporation. Positive colonies were screened by PCR then 
sequenced to ensure that the cloned genes were inserted in reading frame. Successful 
positive transformed cells were allowed to grow in small bacterial culture in Luria Broth 
(LB) of 10 ml overnight culture at 37ºC in the presence of ampicillin. Then transferred to 
1 liter of LB broth and induced with 1mM IPTG at OD600) of 0.5 for an additional 4 h of 
culture. Protein was purified according to the pMAL protein fusion & purification system 
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(Newengland Biolabs). The mannose binding protein (MBP) was attached to our protein; 
we were not able to cleave our protein from MBP using the standard protocol. The fusion 
protein was confirmed by Western blotting using anti-BVDV polyclonal antibodies. The 
protein concentration was measured using Lawry protein assay. The purified MBP-E2 
protein 500 ng was used as a coating antigen for ELISA to test the anti-BVDV antibodies 
from mouse study.  
 
Table.2:  PCR primers used to construct BVDV NADL E2 gene. Underlined is the 
restriction enzyme site.  
   Primer                      Sequence (5ˋ- 3ˋ) 
BVD-E2-Nde1-F          5ˋ- ATTTCACATATGCACTTGGATTGAAAACCTGAA-3ˋ 
BVD-E2-BamH1-R      5ˋ- TCTGTAGGA TCCAGGCATAGGTCCGAGTTTGGT-3ˋ 
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Fig.7. Construction of MBP-E2. BVDV genome with structural protein (gray), & 
non-structural protein (white). The strain used was the cytopathic BVDV NADL. 
BVDV-E2 glycoprotein amplified the PCR product by using BVDV-E2-Nde1-F & 
BVDV-E2-BamH1-R primers in 1% agarose gel with 100 base pair marker. 
Amplified band with a molecular mass of 1000 bp. PCR product was ligated to 
pMAL-p5X plasmid for the expression of MBP-E2 protein. MBP-E2 of a molecular 
mass of 75kDa verified with anti-BVDV polyclonal antibodies 1:1000.  
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Mouse immunization:  
Sixteen female BALB/C mouse 42-49 days was used to test the subunit vaccine. 
Mice were randomly divided into two groups, eight mice immunized intraperitoneal (i.p.) 
with 200 µg purified fusion protein that were diluted in PBS and emulsified in an equal 
volume of Freund’s complete adjuvant (FCA) (Sigma-Aldrich, MO), followed by two 
booster injections on day 14 and 28 post primary immunization of purified proteins that 
were diluted in PBS and emulsified in Freund’s incomplete adjuvant (FIA). Eight mice 
without immunization served as a negative control group and received the same adjuvant 
in PBS. Two booster injection doses were used at biweekly intervals (figure 8). All mice 
were sacrificed two weeks after the second booster injection. Blood & fecal samples were 
weekly collected. Blood was allowed to clot for collection of serum samples which stored 
at −80°C until use. All animal studies in this project complied with the Animal Welfare 
Act, followed the Guide for the Care and Use of Laboratory Animals, approved and 
supervised by South Dakota State University’s Institutional Animal Care and Use 
committee.  
 
 
  
 
 
 
Fig.8. Mouse immunization scheme. Purified chimeric protein 200 µg injected IP in a 
three doses with two weeks intervals (indicated in the upper arrows). Serum and fecal 
samples were collected on a weekly interval (1-6 weeks) or (0-32 days) indicated in the 
lower arrows. Last collected samples were used for antibody titration, BVDV& STa 
neutralization assay.     
Immunization scheme 
Last collected 
samples 
Weekly collected samples 
Day 1 Day 14 Day 28 Day 38 
Euthanize Prime First boost Second boost 
Day 0 Day 7 Day 13 Day 20 Day 27 Day 32 
  1 2 3 4 5 6 
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Anti-mouse antibody titration:   
Serum and fecal samples were examined for anti-K99, anti-STa and anti-BVDV 
antibodies. Purified ETEC K99 fimbria, STa ovalbumin conjugates and BVDV-NADL-
E2 protein were used as antigens in enzyme-linked immunosorbent assays (ELISAs) to 
titrate anti-K99, anti-STa, and anti-BVDV antibodies, respectively. Five hundred 
nanograms of K99 fimbrial antigen or BVDV-NADL-E2 protein was used to coat each 
well of an immunolon
tm
 2HB ELISA plate (ImmunoChemistry Technologies, LLC, MN) 
to titrate anti-K99, anti-BVDV antibodies respectively in a standard ELISA.  For anti-
STa antibody titration, we coated each well of a Costar plate (Corning Inc., Corning, NY) 
with 10 ng of STa ovalbumin conjugate. Plates were coated with the selected antigens 
and kept at 4°C overnight. Double fold serial dilution of mouse serum samples starting 
from (1:640) or fecal samples supernatant starting from (1:10) were used as the primary 
antibodies. Meanwhile horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG 
(1:2500) and IgA (1:1000) were used as the secondary antibodies. The optical density OD 
at 405 nm was measured after 30 min of development in peroxidase substrates (KPL, 
Gaithersburg, MD). The titers were determined by the log10 value of the highest dilution 
with an OD 0.3 after subtraction of the background. The error bars were calculated with 
the optical density (OD) values of triplicate wells of a specimen. 
K99 adherence inhibition assay    
K99 fimbrial ETEC and two different cell lines were used in adherence inhibition 
assays [136]. It has been reported that porcine intestinal epithelial cell line (IPEC-J1) and 
human Caucasian embryonic intestine cell line (INT-407) have the ability to bind to 
ETEC-K99 bacteria in vitro [137]. IPEC-J1 1X10
5 
and 5X10
5
 INT-407 were seeded into 
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each well of a 24-well tissue culture plate,  maintained in a humidified atmosphere of 5% 
CO2 at 37ºC and suspended with DMEM/10% FBS or MEM/10%FBS 
(GIBCO/Invitrogen) respectively. The tissue culture plate were dislodged by 100μl 
0.25% trypsin at 37 ºC in 5% CO2, suspended with same medium and counted under a 
microscope. The subcultivation ratio was set to 1:3. ETEC-K99 bacteria were cultured 
overnight on LB blood agar plates, harvested next day with swabs and suspended in PBS.  
The multiplicity of infection (MOI) ratio was five bacteria per cell. One hundred 
microliters of a bacterial cell suspension was mixed with 20µl mouse serum or fecal 
samples and incubated at room temperature for 1 h on a shaker at 50 rpm. The mixture 
was added to cells and incubated at 37°C in 5% CO2 for 1 h. Cells were washed three 
times with PBS and dislodged with 0.25% trypsin at 37°C in 5% CO2 for 30 min, 
collected by centrifugation (15,000 Xg for 10 min) and resuspended in 1 ml PBS. The 
resuspension was serially diluted (10
2
, 10
3
, and 10
4
), spread on LB agar plates, and 
cultured at 37°C overnight. Colonies were counted, and adherence was calculated as the 
number of CFU/ml. The error bars were calculated with CFU/ml of triplicate wells of a 
specimen. 
BVDV neutralization assay   
Neutralizing antibody induced by E2 glycoprotein after infection or vaccination was 
considered the main protective mediator against BVDV infection [138]. Viral 
neutralization test was done [139] with some modification. The neutralization assay was 
done using the serum or fecal samples antibodies, utilizing Madin Darby Bovine kidney 
(MDBK) cells with 10% fetal bovine serum (FBS) as a supplementary  medium and the 
cytopathic NADL strain (ATCC VR-534). Briefly, 2.5 X10
5
 MDBK cells (ATCC CCL-
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22) were seeded to a 96 well tissue culture plate. The BVDV-free MDBK cell line was 
grown in MEM containing 20 µg/ml gentamycin and 10% FBS. Two-fold serial diluted 
samples were pooled starting with 1:40 dilution to 1:5120. Fecal sample supernatant or 
heat-inactivated serum (56°C/ 30 minutes) was mixed with equal volumes of virus 
containing 0.1 median tissue culture infectious doses (TCID50) and incubated for 1 h at 
37°C in a 5% CO2 incubator. The mixture was added to BVDV-free MDBK cells in 96 
well tissue culture plate and kept for 3 days at 37°C in a 5% CO2 incubator. All 
experiments were performed in triplicate and the neutralization data were referred to the 
non-immune serum. The ability of the tested sample to reduce the number of viral 
cytopathic effect was assayed in monolayers of MDBK cells. The highest dilution of 
serum which gave complete neutralization of virus, as determined by the absence of 
cytopathic effect (CPE) was recorded as the SN titer.   
STa neutralization assay     
Neutralizing activity of the STa toxin through the antibodies in mouse serum and 
fecal samples was examined. The human colon carcinoma cell lineT84 cells (ATCC 
CCL-248) was utilized and maintained in a humidified atmosphere of 5% CO2 at 37 ºC 
and cultured in 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM) and Ham's 
F12 medium (Invitrogen, CA) supplemented with 5% Fetal Bovine Serum (FBS) 
(Thermo Fisher Scientific, MA), (the subcultivation ratio was 1:3). Cells were seeded in a 
12-well tissue culture plate. Cyclic GMP (cGMP) enzyme immunoassay kit (Assay 
Design, Ann Arbor, MI) was used [136]. Briefly, 2X10
5
 T84 cells (greater than 85% 
confluence) were seeded into each well. The spent medium in the plate was removed, and 
the plate was washed twice with magnesium and calcium free saline (GKN, 1 mg/ml 
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glucose, 0.4 mg/ml potassium chloride, and 8 mg/ml sodium chloride). Cells were 
incubated with 700 μl DMEM/F12 medium with 1mM isobutylmethylxanthine (IBMX) 
at 37 ºC in 5% CO2 for 45 min. Two ng of STa toxin (diluted in 150 µl of DMEM/F12) 
was incubated with 150µl of a mouse serum or fecal sample (1:10 dilution in 
DMEM/F12, in triplicate) at room temperature for 1 hr, then the mixture (150 µl of STa 
toxin dilution plus 150 µl of the serum or fecal sample dilution) was added to each well, 
and the plate was further incubated with IBMX-pretreated cells for additional 2-4 hours 
at 37ºC in 5% CO2.The plate was washed twice with GKN, and, the cells were lysed with 
0.1 M HCl (300 µl per well) HCl containing 0.5% Triton-X100 (Sigma-Aldrich, MO) 
and neutralized with 0.1 M NaOH. Cell lysates were collected by centrifugation at 660 
Xg for 10 min at room temperature. The supernatant was tested for intracellular cGMP 
levels by following the manufacturer’s protocol (Assay Designs, Inc., Ann Arbor, MI).  
Construction of holotoxin like vaccine:  
Plasmid pBR322 (Promega, Madison, WI) was used to clone and express the 
recombinant chimeric fanC gene expressing mutated STa gene, and bovine viral diarrhea 
B and T-cell epitopes. Plasmids and strains used are listed in supplementary table-1. The 
plasmid p9196 was used as a template for the chimeric fanC gene and the plasmid 9207 
was used to amplify the holotoxin like structure. Different primers were used 
(supplemtary table). Amplified products were separated by 1% agarose gel 
electrophoresis and purified using a QIAquick Gel Extraction Kit by following the 
manufacturer’s instruction (QIAGEN, Valencia, CA). Two different constructs were 
designed. The first construct (9300) contains fanC promoter, ribosomal binding site and 
signal peptides with HindIII/EagI restriction sites. The second construct (9205) includes 
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the p1& p2 prokaryotic promoter for pBR322 plasmid using with Nhe1/EagI restriction 
sites. The reason for constructing two different plasmids was to try to compare the 
protein expression in both constructs. Purified PCR products and plasmid pBR322 were 
digested with the unique restriction enzymes.  Ligation products were used for 
transformation into a non pathogenic E. coli DH5α competent cells under a standard 
procedures [134]. Positive colonies were initially screened by PCR and sequenced to 
ensure that the cloned genes were inserted in correct reading frame. Successful positive 
transformed cells were grown in Luria Broth (LB) overnight with shaking (200 rpm) at 
37ºC in the presence of ampicillin. The bacterial culture was centrifuged at 5,000 Xg for 
10 min at 4°C, and the pellets were resuspended into bacterial protein extraction B-PER 
reagent in phosphate buffer (Pierce, Rockford, IL) for total protein extraction. FanC-STa-
BVDV-eltA2:B fusion protein has been purified according to [151], then the purified 
protein was examined by standard sodium dodecyl sulfatepolyacrylamide gel 
electrophoresis (SDS-PAGE) and Western blotting. 
Statistic analysis:  
Data were analyzed by student’s t-test and used for comparison of the different 
treatments; the results were expressed as means ± standard deviations. P values were 
calculated to measure significances in differences, calculated P values of <0.001 was 
regarded as significant. 
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Table 3 Strains and plasmids used in subunit vaccine development    
Strains or 
plasmids 
Relevant properties Reference 
E. coli strains  
BL21 E coli competent cell, fhuA2 [lon] ompT gal [dcm] ΔhsdS Invitrogen 
1297 E. coli KI2, strain 711, lac his trp proC phe Nal
r
 [1] 
9196 
FanC-STa-BVDV fusion cloned to pET28a, NheI/EagI in 
BL21 competent cell 
This study  
9210 
E2  glycoprotein from BVDV type-1, NADL strain, 
Nde1/BamH1 cloned to pMAL-p5X in BL21 competent cell 
This study  
BVDV strain  
NADL Flaviviridae, Pestivirus, Bovine viral diarrhea virus-1, 
NADL strain (ATCC VR-534).  
ATCC 
Plasmids   
pET28a 
Cloning vector of pBR322 origin with BamHI-XhoI MCS, 
His-Tag, T7-Tag, T7-promoter, T7-transcription, T7-
terminator, lacI, Kan
r
. 
Invitrogen 
pMAL-
p5X 
Cloning vector with MBP, encoded by the malE gene, 
protease Factor Xa used for cleavage of fusion protein from 
MBP, tac promoter (Ptac), IacI
q
, AP
r
.  
New 
England 
Biolabs 
 
p9196 FanC-STa-BVDV, NheI/EagI in pET28a   This study  
p9210 
BVDV- NADL E2  glycoprotein, Nde1/BamH1 in pMAL-
p5X This study  
pK99 
E. coli KI2 strain 711 with 7.1-kb K99 BamHl fragment 
cloned into pBR322 generating  plX12 
[1]   
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Results 
Constructed fusion protein FanC-STa-E2 carried representative epitopes. 
The whole E. coli K99 plasmid was received as a gift from Dr. R. E. Isaacson, at the 
Veterinary and Biomedical Sciences Department, University of Minnesota, Minnesota, 
USA (figure 2) and used to construct our strain in this study. The pK99 was analyzed and 
shown to be composed of eight subunits, while the fanC is the major fimbriae. Mapping 
of the major fanC fimbriae to detect the non conserved less antigenic exposed epitopes 
(figure 3), which removed and replaced with pSTa12 and BVDV epitopes. Those non 
conserved fanC amino acid sequence 91-107, 116-126 and 154-62 has been removed for 
the insertion of STaP12F (NNTFYCCELCCNFACAGC), the BVDV E2 B-cell epitope 
(
70
HTRALPTSVVF
80
), and the E2 T-cell epitope (
193
DQLLYKGGS
201
), resulted in the 
FanC-STa-E2 fusion protein (figure 4).  Our final product is fanC-STa-E2 fusion protein. 
Fusion FanC protein was transformed by electroporation into BL21 competent E. coli and 
purified by the Ni-NTA purification system. The fusion protein was refolded, 
concentration was mesuresed through Lawry protein assay and confirmed by Western 
blotting and commasie blue staining before proceeding to the animal study (figure 5).  
The multiepitope FanC-STa-E2 fusion protein was safe and immunogenic.  
Mice did not display any noticeable distress or adverse effects after i.p. immunized with 
this 6xHis-tagged multiepitope FanC-STa-E2 fusion protein. Anti-K99, anti-STa and 
anti-BVDV antibodies were developed. Adult mice were vaccinated with purified FanC 
proteins which emulsified in Freund’s complete adjuvant (FCA) in the primary injection 
at day 1, followed by two booster injections with purified chimeric FanC proteins which 
emulsified in Freund’s incomplete adjuvant (FIA) on days 14 and 28 post primary 
47 
 
 
immunization. Both serum and fecal samples were collected weekly at day 0, 7, 13, 20, 
27 and 32. The final sample collected 10 days later after the last immunization at day 38 
and was used to test the antibody titers using ELISA. Bacterial adherence inhibition 
assay, neutralization activity of both STa enterotoxin and BVDV were evaluated. The 
titers were determined by the log10 value of the highest dilution with an OD >0.3.    
The weekly collected sera were tested; they showed a detectable increase in the 
antibody titer along the experimental period with an increase in the serum IgG Anti-K99, 
anti-STa and anti-BVDV antibodies (figures 9, 10, 11). The booster immunization was 
able to potentiate and stimulate the mice immune response and increase the antibody titer 
in the three antigens. It was noticed that STa has the ability to evoke an immune 
responses which indicates that coupling of STa epitope to fanC fimbriae render STa more 
immunogenic.  
The last sample, collected 10 days after the last immunization, was tested for 
antibody levels. Systemic IgG antibodies in serum samples and the secretory IgA 
mucosal antibodies from fecal samples supernatant were tested by ELISA. Anti-K99 IgG 
antibodies were detected in the serum of the immunized mice at titers (log10) of 3.611 ± 
0.02595, while no anti-K99 IgG antibodies were detected in the serum sample from the 
control mouse (figure 12). Anti-K99 secretory IgA antibodies were detected (OD 405) of 
0.2420 ± 0.04332 in the feces of mouse immunized with fanC chimeric protein. In 
contrast, no anti-K99 antibodies IgA were detected in the fecal sample from the control 
mouse (figure 15). Both anti-K99 IgG and IgA antibodies obtained from immunized 
mouse showed a significant difference comparing with the control (P < 0.001).  
48 
 
 
Anti-STa IgG antibodies in sera of immunized and control mice with 1:10 dilution 
were detected at (OD 405) of 0.2733 ± 0.05660 and 0.01438 ± 0.00496 respectively. The 
anti-STa IgG antibodies were significantly different from the control mouse (P < 0.001). 
Suggesting that STa epitope became immunogenic when expressed as a foreign antigen 
in chimeric FanC protein and could elicit anti-STa IgG antibodies (figure 13). There was 
no significant (ns) difference in the anti-STa IgA antibodies detected in the fecal samples 
of immunized mouse comparing with the control mouse (figure 16).   
There was a significant difference in the anti-BVDV serum IgG antibody from 
immunized group comparing with the control, the titer (log10) was 3.479 ± 0.08771(P < 
0.001) (figure 14). Anti-BVDV IgA antibodies were detected at (OD 405) of 0.3287 ± 
0.06879 in the fecal supernatant of mouse immunized with fanC chimeric protein (P < 
0.001) (figure 17). Anti-BVDV IgA antibodies titer (log10) was measured in four 
immunizied mice (OD >0.3) and showed a significant difference with the control, 7263 ± 
0.276 (P < 0.05) (figure 18). Anti-BVDV IgA was detected with a higher level comparing 
with anti-K99 IgA. Good immune response is expected to produce antibodies able to 
neutralize any invaders or its virulence factor.  After the antibodies against our chimeric 
protein were inducted, the three antigens (K99, STa, and E2) were confirmed. Adherence 
and neutralization assay were tested to evaluate the biological functions of these 
antibodies in collected serum and fecal samples in vitro.  
Antibodies in serum samples of the immunized mice significantly inhibited 
adherence of K99 fimbrial E. coli bacteria to INT-407 and IPEC-J2 cells.  The 
bacterial adherence inhibition assay was carried out. It showed that the E. coli K99 able 
to bind to different types of K99. The IPEC-J1 and INT-407 were able to bind to K99 
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bacteria as they considered K99 receptor positive cell line [137]. The bacteria suspension 
was incubated with the sera or fecal supernatants from mouse immunized with chimeric 
fanC fimbriae (1:10) for 1 hour. Mixture was added to both 1X10
5
 IPEC-J1 and 5X10
5
 
INT-407 seeded cells. After 1 hour of incubation, the plate was washed; the cells were 
dislodged, resuspended, and plated on LB agar plates in serial dilutions. Colonies which 
grown from LB agar were counted to calculate CFUs/ml. Serum anti-K99 antibodies 
from immunized mouse was shown to inhibit the bacterial binding in cell culture in vitro 
and reduced the adherence of K99 fimbrial ETEC bacteria to K99 receptor positive cell 
lines. There was a significance difference between the immunized and control sera. 
Bacteria adherence was significantly reduced more than ten folds. Binding of the bacteria 
to INT-407, or IPEC-J1 cells was 11.33 ± 0.8819 (x10
3
) and 2.333 ± 0.6667 (x10
3
) 
respectively in immunized serum. The binding was significantly lower than the bacteria 
incubated with the serum of the control, (168.3 ± 6.009 x10
3
) and (50.00 ± 5.000 x10
3
) 
respectively (P <0.001) (figure 19). Fecal antibodies showed no significant differences 
between the immunized and the control, results were not confirmed after incubation with 
fecal samples; this was due to the detachment of the cells when incubated with the fecal 
sample supernatant.         
Antibodies in serum samples of the immunized mice neutralized STa toxin. In 
addition to their bacterial adherence blocking activity, the antibodies which produced by 
the immunized mouse have the capability of neutralizing STa enterotoxin. STa is able to 
increase the intracellular cyclic GMP level in host cells. In neutralization assays, the 
purified 2ng  STa toxin was incubated with antibodies from serum or fecal samples and 
then used to treat T84 cells. The T84 cells were lysed with 0.1 M HCl and centrifuged. 
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The supernatants were collected to test the intracellular cyclic GMP concentration. A 
cyclic GMP EIA was carried out to measure the intracellular cGMP level in T84 cells, 
which indicates the toxicity of enterotoxins in those cells.  Antibodies from immunized 
sera neutralize the STa toxin efficiently. This indicated by a significant reduction in the 
intracellular cGMP level. The cGMP level in the control and the immunized sera was 
4.100 ± 0.7506 and 0.5425 ± 0.07157 pmol/ml respectively (P <0.001) (figure 20).  The 
fecal IgA antibodies did not show any significance difference between the immunized 
and the control groups. 
Antibodies in serum samples of the immunized mice showed neutralizing 
activities against BVDV viral infection. BVDV neutralization assay was done to test 
the neutralizing ability of anti-BVDV antibodies utilizing the MDBK cells (ATCC CCL-
22) and BVDV-NADL strain (ATCC VR-534). Briefly, serum samples were double fold 
serially diluted. The neutralization titer for the immunized serum was (≤ 640 dilutions) 
after three days of incubation with BVDV in MDBK cells. Neutralizing antibodies were 
detected in the immunized mice; they have the ability to block the cytpathic effect of 
NADL strain on MDBK cells in vitro. In our mice study, the anti-BVDV IgG antibody 
titer (log10) in the immunized group was significantly higher than the control 3.479 ± 
0.08771 (P < 0.001). All serum samples in the control had no detectable neutralizing 
antibody (titers of 0) and a clear cytopathic effect was detected (figure 21).  
In summary, we were not only effectively able to induce humoral immune 
responses by chimeric FanC proteins. But also obtained biologically functional antibodies 
that could block bacteria adherence to intestinal epithelial cells neutralize enterotoxins 
and BVDV in tissue culture in vitro.   
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Fig.9. Anti-K99 IgG antibody detection. Serum samples from control and immunized 
mouse with chimeric fanC protein were tested along the experimental period (1-6 weeks). 
Each of the control and immunized mice was subdivided in two cages per group (control 
1&2) and (immunized 3&4). Samples were been used as primary antibodies in ELISA 
while HRP-conjugated goat anti-mouse IgG (1:5000) was used as secondary antibody.   
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Fig.10. Anti-BVDV IgG antibody detection. Serum samples from control and immunized 
mouse with chimeric fanC protein were tested along the experimental period (1-6 weeks). 
Each of the control and immunized mice was subdivided in two cages per group (control 
1&2) and (immunized 3&4). Samples were used as primary antibodies in ELISA while 
HRP-conjugated goat anti-mouse IgG (1:5000) was used as secondary antibody.    
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Fig.11. Anti-STa IgG antibody detection. Serum samples from control and immunized 
mouse with chimeric fanC protein were tested along the experimental period (1-6 weeks). 
Each of the control and immunized mice was subdivided in two cages per group (control 
1&2) and (immunized 3&4). Samples were used as primary antibodies in ELISA while 
HRP-conjugated goat anti-mouse IgG (1:5000) was used as secondary antibody.   
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Fig.12. Anti-K99 IgG antibody titration (log10). Serum samples from control & 
immunized mice with chimeric fanC protein were used as primary antibodies in ELISA 
while HRP-conjugated goat anti-mouse IgG (1:5000) was used as secondary antibody. 
The error bars were calculated with the OD values >0.3, after subtraction of the 
background, of triplicate wells of samples.**,(P < 0.001). 
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Fig.13. Anti-STa IgG antibody titration (OD 405). Serum samples from control & 
immunized mice with chimeric fanC protein were used as primary antibodies in ELISA 
while HRP-conjugated goat anti-mouse IgG (1:5000) was used as secondary antibody. 
Three samples showing OD >0.3, three with OD ≥0.2 and two showing an OD <0.2. 
Reading was taken after subtraction of the background in triplicate. The error bars 
indicate standard deviation. **,(P < 0.001). 
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Fig.14. Anti-BVDV IgG antibody titration (log10). Serum samples from control & 
immunized mice with chimeric fanC protein have were as primary antibodies in ELISA 
while HRP-conjugated goat anti-mouse IgG (1:5000) was used as secondary antibody. 
The error bars were calculated with the OD values >0.3, after subtraction of the 
background, of triplicate wells of samples.**,(P < 0.001). 
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Fig.15.Anti-K99 IgA antibody titration (OD405). Fecal samples supernatant, from 
control & immunized mice with chimeric fanC protein were used as primary antibodies 
in ELISA while HRP-conjugated goat anti-mouse IgA (1:5000) was used as secondary 
antibody. Two samples showing OD >0.3, two showing an OD >0.2 and remaining 
OD<.0.2 Reading was taken after subtraction of the background in triplicate. The error 
bars indicate standard deviation. **,(P < 0.001).  
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Fig.16. Anti-STa IgA antibody titration (OD405). Fecal samples supernatant, from 
control & immunized mice with chimeric fanC protein were used as primary antibodies 
in ELISA while HRP-conjugated goat anti-mouse IgA (1:5000) was used as secondary 
antibody. All samples showed no significant changes (ns). Reading was taken after 
subtraction of the background in triplicate. The error bars indicate standard deviation. 
 
0.0
0.1
0.2
0.3
0.4
0.5 ImmuniziedControl
Fecal sample
a
n
t
i-
S
T
a
 I
g
A
 O
D
 4
0
5
Anti-STa IgA antibody titration 
Fecal samples 
59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.17. anti-BVDV IgA antibody titration (OD 405). Fecal samples supernatant, from 
control & immunized mice with chimeric fanC protein were used as primary antibodies 
in ELISA while HRP-conjugated goat anti-mouse IgA (1:5000) was used as secondary 
antibody. Four samples with OD >0.3, two with an OD >0.2 and two with OD<.0.2 
Reading was taken after subtraction of the background in triplicate. The error bars 
indicate standard deviation. **,(P < 0.001).   
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Fig.18. Anti-BVDV IgA antibody titration (log10). Fecal samples from control & 
immunized mice with chimeric fanC protein have were as primary antibodies in ELISA 
while HRP-conjugated goat anti-mouse IgA (1:5000) was used as secondary antibody. 
The error bars were calculated with the OD values >0.3, after subtraction of the 
background, of triplicate wells of samples.**,(P < 0.05). 
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Fig.19. Bacterial adherence inhibition assay. Serum samples from control & immunized 
mice with chimeric fanC protein, Escherichia coli K99 strain and two cell lines, IPEC-J1 
and INT-407 were used. 1X10
5
 IPEC-J1 and 5X10
5
 INT-407 cells were seeded into each 
well. The multiplicity of infection was set to 5 bacteria per cell. Samples incubated with 
the bacteria then added to the cells. Cells were dislodged, serially diluted in PBS and 
plated on LB agar plates overnight at 37°C. Colonies were counted and calculated as 
CFU/ml (in thousthands). Error bars indicate standard deviations. **,(P < 0.001). 
0
50
100
150
200 ImmuniziedControl
 INT-407            IPEC-J1
C
e
ll
-
 a
s
s
o
c
ia
t
e
d
 C
F
U
 (
X
1
0
0
0
)
** 
Bacterial adherence inhibition assay 
** ** 
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.20.Anti-STa antibody neutralization assay. Serum samples (1:10)  from mouse 
vaccinated with purified chimeric FanC protein were used to neutralize 2ng STa. Mixture 
was added to T84 cells to detect the stimulation of intracellular cGMP level (pmole/ml) 
with a direct cGMP enzyme immunoassay kit (Assay Designs) to asecss the anti-STa 
antibody neutralization activity. Cell culture medium alone has been used as a negative 
control, serum samples from control and immunizied mouse were tested. Error bars 
indicate standard deviations. **,(P < 0.001). 
 
0
2
4
6 ImmuniziedControl
Medium
Sample
a
n
t
i-
S
T
a
 a
n
t
ib
o
d
y
 n
e
u
t
r
li
z
a
t
io
n
in
 c
G
M
P
 l
e
v
e
l 
in
 T
-
8
4
 c
e
ll
(
p
m
o
le
/m
l)
** 
** 
Anti-STa antibody neutralization 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.21.Anti-BVDV antibody neutralization assay. (A) Negative control cell, (B) Positive 
control, (C) serum sample immunized group+ virus, (D) serum sample control 
group+virus. MDBK cells& cytopathic NADL strain in 0.1 TCID50. The serum 
neutralization titer ≤ 640 were able to neutralize the NADL virus in vitro. Arrows 
indicate cell clustering as CPE. No CPE was detected in the immunized group. 
Anti-BVDV antibody neutralization assay 
A 
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Discussion    
 
The main objective of this project was the achievement of protection against 
diarrheal disease caused by E. coli K99 and BVDV. This was the first study reports the 
combination of one vaccine able to provide a protection against E. coli K99 and BVDV. 
Adhesins and enterotoxins induce fluid and electrolyte hypersecretion. ETEC control 
based on the blocking of the bacterial adherence to the host receptors and eliminating of 
enterotoxin activity in the host epithelial cells [36]. BVDV control includes the limitation 
of disease spread and/or reduction of the disease severity beside the prevention of the 
transplacental infection. The combination of  T and B cell epitopes from E2 glycoprotein 
is a good approach for the protection with providing sterilizing immunity [123]. It is 
believed that the subunit vaccine candidates composed of an adhesin antigen, toxin 
antigen and BVDV epitopes or carrying a adhesin-toxin-BVDV fusion protein which 
could be a good stimulant for anti-adhesin, anti-toxin and anti-BVDV immunity which 
protect against both diseases.   
 Current vaccine strategy was to have one vaccine candidate that is able to provide a 
protection against E. coli K99 and BVDV infection. The subunit vaccine composed of a 
purified FanC fusion protein.  Current immunization practice using purified pili or 
inactivated K99 fimbrial E. coli bacteria does not induce any antitoxin immunity to 
protect against enterotoxicity.  As a small-size and poorly immunogenic molecule, STa 
alone does not stimulate anti-STa immunity.  Therefore, even inactivated K99 fimbrial 
bacteria expressing STa toxin cannot stimulate immunity protecting against STa toxin.  In 
contrast, since STa is potently toxic, any products carrying native STa are considered not 
safe.  The secreted heat-stable enterotoxin a (STa) is the major secreted toxin in bovine 
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ETEC K99 infection which predispose to the secretory diarrhea [140]. Therefore, this 
makes STa toxoid an attractive target to be included in ETEC K99 vaccine. Data from 
this study indicate that the fusion antigen carrying the K99 antigen FanC and STa toxoid 
STaP12F elicited both anti-K99 and anti-STa antibodies.  Moreover, antibodies in serum of 
the immunized mice exhibited activities to inhibit adherence of K99 fimbrial E. coli 
bacteria and to neutralize STa toxin.Genetic integration of three epitopes in the K99 fanC 
major fimbriae confirms the idea that it could be applied as a platform for developing 
effective multivalent vaccines against bovine diarrhea. Similarly, several studies were 
shown to target FanC major fimbrae of K99 in vaccine development. A subunit vaccine 
development from an edible transgenic soybean was used, immunize mice with extracted 
protein from the transgenic leaves which developed a high antibody titer and stimulate 
the mice immune system [84].  
The idea behind utilizing chimeric fimbriae as a backbone for ETEC vaccine 
development with the insertion of several epitopes showed a great success in different 
studies. One study uses the Escherchia coli K88ac fimbriae to express LT & STa toxin 
epitopes, and used for rabbit immunization which stimulate the production of systemic 
IgG and mucosal IgA antibodies that neutralize Cholera toxin, STa toxin and prevent the 
K88ac E. coli adhesion [136]. Several in vitro studies were developed on cell culture to 
test the ability of the antibodies to prevent the bacterial adherence on the tissue culture 
and the antibody neutralization assay.  
 Measuring the antibody titer on a weekly collected serum samples, showing a 
gradually increase of the systemic IgG antibody along the experimental period for anti-
K99, anti-STa and anti-BVDV antibodies  (Fig.9, 10, 11), which indicate that the 
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chimeric fanC antigen was able to stimulate the immune response and the booster doses 
of antigen were able to evoke better immune response. Last collected serum and fecal 
samples ten days after the last immunization were tested. The antibody titer anti-K99, 
anti-STa and anti-BVDV antibodies IgG and IgA respectively were evaluated. It is noted 
that greater titers of anti-K99 and anti-BVDV E2 IgG antibodies were detected in the 
serum samples of the immunized mice.  But anti-STa immune response was detected low 
in the immunized mice.  Indeed, only two immunized mice had anti-STa IgG detected 
above the arbitrarily set-up OD cutoff point (0.3 after subtraction of background 
readings).  The serum IgG antibody titer was much higher than the fecal IgA mucosal 
antibody titer along the experimental period. We relate the difference between the 
systemic and the mucosal antibody titer in our study due to the intraperitoneal (IP) route 
of antigen administration, which is a potent stimulant of the systemic immune system, but 
it is not good stimulant of mucosal antibody. Most of the commercial vaccines elicit 
systemic antibody due to the systemic homing specificity of the effector lymphocytes in 
the peripheral lymphnode [12].     
Based on our results, the fusion antigen was able to significantly stimulate the 
production of anti-K99 IgG antibodies, which found to be anti-adhesin antibodies and  
significantly block the adherence of wild type K99
+
 ETEC strain to a porcine intestinal 
epithelial cell line (IPEC-J1) and human caucasian embryonic intestine cell line (INT-
407) in vitro. It was reported that porcine intestinal epithelial cell line (IPEC-J1) and 
human Caucasian embryonic intestine cell line (INT-407) have the ability to bind to 
ETEC-K99 bacteria in vitro [137]. Similarly, anti-adhesin antibodies against ETEC 
fimbriae have been developed and were able to block bacterial adhesion in vitro in tissue 
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culture. One study use E. coli K88ac fimbriae with embedded LT and STa epitopes and 
used for rabbit immunization, anti-K88ac, anti-LT and anti-STa antibodies has been 
developed which inhibit the adherence of K88ac fimbrial E. coli to porcine small 
intestinal enterocytes and neutralize cholera toxin and STa toxin [136]. Another study 
genetically fused nucleotides for tripartite FaeG-FedF-LT(192)A2:B, and used for 
immunizations in mice and pigs, anti-K88, anti-F18, and anti-LT antibodies in 
immunized mice and pigs has been developed plus the ability of the anti-porcine 
antibodies elicited to neutralize  cholera toxin and inhibited adherence against both K88 
and F18 fimbriae [141].   
Our antigen was able to induce anti-STa anti-toxin immunity. Our toxoid epitope 
STap12F with a mutation in pro12 amino acid. It has been reported that the mutation of the 
pro12 and Ala13 of STa protein were significantly reduced the pSTa toxicity but retains 
the immunogenicity [128]. The stimulated anti-STa IgG antibodies were significantly 
increased between the immunized and the control group. The low anti-STa titers below 
our cutoff point 0.3 most likely resulted from the nature of low immunogenicity from 
STa or its derived toxoid antigens.  Fusing additional copies of the STa toxoid (in a 
fusion antigen) was shown to facilitate overall anti-STa immunogenicity (data 
unpublished).  Future studies to fuse two or more STaP12F copies into this FanC-STa-E2 
fusion likely will induce greater titers of anti-STa antibodies.  It was reported that STa 
became immunogenic when coupled to an appropriate large molecular weight carrier 
through chemical conjugation or recombinant fusion techniques and also it reduces the 
toxicity of STa molecule by mutagenesis to have a safe vaccine [67]. Several studies 
were developed to conjugate or genetically fuse STa to the carrier proteins to improve its 
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immunogensity [142]. One study showed that the porcine STa toxoids became 
immunogenic and produce neutralizing anti-STa antibodies after being genetically fused 
to a full-length porcine-type LT toxoid, LTR192G [143].  
The resulted anti-STa IgG antibody from this study have the ability to neutralize 
the toxicity of STa toxins efficiently in T84 human colonic adenocarcinoma cell line in 
vitro. There were no detected anti-STa IgA mucosal antibodies of the fecal samples 
supernatant. The development of anti-STa antibodies when integration of STa epitope in 
previous vaccine was reported. One study [136] embedded the STa toxoid epitope in the 
FaeG major subunit of E. coli K88ac fimbriae and used the chimeric protein for rabbit 
immunization, anti-STa antibodies were developed which also were able to neutralize the 
STa toxin. Another study reported an increase in the serum STa neutralizing antibodies 
when a recombinant native purified STa coupled to modified bovine serum albumin and 
used for immunization of female New Zealand white rabbits [144].  In summary, our 
chimeric antigen with STa toxoid epitope were able to elicit systemic anti-STa IgG 
neutralizing antibodies that could provide protection against STa toxicity in vitro in T84 
cells but no mucosal anti-STa IgA antibodies were developed.   
Realized the heterogeneity among BVDV isolates and existing challenges in 
developing broadly effective vaccines, we carried out this study to explore an alternative 
approach to develop vaccines against BVDV associated bovine diarrhea.  Heterogeneity 
(genetically and more importantly antigenically) makes it nearly impossible for any live 
attenuated or inactivated vaccines derived from a single BVDV strain to provide broad 
protection.  A cocktail of live attenuated strains could improve protective efficacy, but it 
increases the risk of virulence reversal of the product and also viral infections in utero.  
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For inactivated vaccines, mixing of multiple strains becomes less desirable due to 
difficulties in carrying sufficient antigens from individual strains.  Subunit vaccines could 
overcome above disadvantages. Our primary target of including BVDV epitopes was to 
provide a protection against BVDV along with ETEC. Thus prevention of the 
transplacental transmission, PI infection and reduce the morbidity and mortality rate. This 
will increase the efficiency of animal production and health. In this study we did include 
one B-cell epitope and one T-cell epitope in our recombinant fanC protein to test the 
immunogensity of this protein in mice. B-cell epitopes are surface exposed regions of the 
protein, they are probably more mobile than interior regions, and so more hydrophilic and 
accessible to the immune system [145]. Epitopes were chosen from E2 glycoprotein 
because the majority of B and T-cell response is directed against E2 glycoprotein, plus 
the neutralizing effect of antibodies produced from E2 glycoprotein. The combination of  
B and T-cell epitopes is required to prevent of fetal infection [123]. Our results showed 
an increase in both, anti-BVDV IgG antibody and anti-BVDV IgA antibody titer. This 
increase in the systemic and mucosal antibodies resulted from including only two BVDV 
epitopes. The titer of anti-BVDV IgA antibody was much higher than the anti-K99 IgA 
which represents a promising tool for the control of BVDV infection.  
Anti-BVDV IgG antibodies were able to neutralize the cpBVDV NADL strain in 
vitro in BVDV free MDBK cells. This means that antibodies have a protective 
neutralizing effect against the virus. It was reported that CPE is the earliest 
morphological change in response to cpBVDV infection in MDBK cells [146]. Our result 
showed that there was CPE in control group, while no CPE detected in the immunized 
group at serum dilution of ≤ 640. This indicates that the serum antibodies have the ability 
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to produce in vitro protection in MDBK cells. Clear cell morphology was detected under 
the microscope with immunized serum. The anti-BVDV IgG antibodies have the ability 
to reduce the severity of BVDV infection. Comparing with the control serum, more 
clustering of cells and clear cytoplasmic vacuolization were detected under the 
microscope. We cannot evaluate the mucosal anti-BVDV IgA neutralizing effect because 
the fecal sample supernatant cause death of MDBK cell line when incubated. Our 
neutralizing results was confirmed by the previous reshrachers, they stated that the 
glycoprotein E2 is the most immunogenic protein of BVDV and able to elicit high titers 
of strong neutralizing antibodies after infection and/or vaccination [108, 110, 139]. 
Several studies showing similar results of neutralizing antibodies when targeting E2 
glycoprotein in BVDV vaccine, the only difference is that we were able to include only 
two BVDV epitopes not the whole E2 glycoprotein and get neutralizing antibodies. One 
experimental study in sheep tested two conventionally inactivated BVDV vaccine and 
one multivalent E2 subunit vaccine, all vaccines induced neutralizing antibodies against 
all challenge strains [147]. Another study showed that the recombinant BVDV-E2 
protein, through a recombinant baculovirus (Ac-E2pol), neutralizing immune response 
against BVDV NADL strain were developed in the vaccinated mice after three doses of 
the antigen [148]. One more study used the recombinant vesicular stomatitis virus (VSV-
E2) encoding BVDV E2 glycoprotein to induced the a recombinant E2 protein, BALB:c, 
the mice developed a specific BVDV neutralizing response after intranasal vaccine 
inoculation which lasted for at least 180 days post inoculation [149]. The BVDV NADL 
E2 glycoprotein neutralizing antibodies might have a cross protection with other BVDV 
strains which give a brooder protection against BVDV infection. One study showed that 
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the BVDV E2 glycoprotein of NADL strain was used to construct vaccinia virus 
recombinants expressing E2  to immunize mice of three H-2 haplotypes, serum samples 
from mice showed a high levels of neutralizing antibodies to NADL strain and were able 
to neutralize the Oregon C24V reference strain but failed to neutralize the Osloss 
reference [150].  
Due to the high cost of subunit vaccine preparation, we tried to construct a live 
vaccine protect against ETEC and BVDV. Advantage of this technology, stimulation of 
strong humoral and cell-mediated immune responses that can be highly effective in 
preventing or clearing the later infection with low coast. A fusion antigen of recombinant 
fusion protein composed of (FanC-pSTa-BVDV E2) which is fused to LtA2-LtB has 
been constructed. Two constructs with different promoters has been used to compare the 
protein expression and use the one with high expression level. Our results showed that 
the construct was not completely assembled to holotoxin in both constructs as confirmed 
by western blotting. We were not able to detect our epitopes attached to LtA2 subunit, 
only the pentamer B subunit was verified by Western blotting. My future 
recommendation, retain partial of the LTA1 peptide (of C-terminus) or constructing of 
full length toxin like structure with mutation in A subunit to decrease its enzymatic 
activity. This will stable the holotoxin structure and elaborate potent immune response.  
In summary, the FanC-pSTa-BVDV E2 fusion antigen was constructed by 
replacing non conserved exposed epitopes on FanC with STa and BVDV B and T-cell 
epitopes. It should be pointed out that this study examined mainly the immunogenicity of 
the constructed FanC-STa-E2 fusion antigen.  Although data showed that this fusion 
antigen elicited specific antibodies in mice and the antibodies showed neutralizing 
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activity against ETEC and BVDV viral infection, its candidacy as a subunit vaccine 
against ETEC neonatal diarrhea in calves and BVDV diarrhea at other ages can only be 
determined in large-samples and well-designed field trials.  Future studies will be also 
needed for the development of a broad-spectrum vaccine against bovine diarrhea. 
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Supplementary Data 
 Primer                      Sequence (5ˋ- 3ˋ)  
FanC-ltA2-Nhe1-F                
5ˋ- CATATGGCT AGCGATGAAAAAAACACTCCTAGCTATTATCTTA-3 
 
 
FanC- LtA2- HindIII-F  
5ˋ-ATCATCGATAAGCTTTAGGGAATGGCTATGTTTTCTGGT-3 
 
 
LtB-EagI-R              5ˋGATCGGTATTGCGGCCGCTACCGC-3ˋ 
 
FanC-LtA2-F2               
5ˋ-GCATCCTTCTTAGTCACTTATATGCATCATGCACCACAAGGTTGTGG-3ˋ 
 
 
FanC-LtA2-R2               
5ˋ-CCACAACCTTGTGGTGCATGATGCATATAAGTGACTAAGAAGGATGC-3ˋ 
 
Supplement- Table-1:  
Primers used to construct FanC-STa-BVDV-LtA2-LtB in pBR322, underlined are the 
restriction enzyme site.  The first construct was used for the construction of fanC 
chimeric gene in pBR322 with NheI/EagI restriction enzyme. The second construct was 
the chimeric fanC- LtA2-LtB gene in pBR322 with HindIII /EagI restriction enzyme site. 
FanC-LtA2-F2& FanC-LtA2-R2 are two overlapping primers that connect the chimeric 
fanC gene with LtB subunit. While LtB-EagI-R is the reverse primer used in both 
constructs. 
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Supplement-Table-2: Strains and plasmids used in this research project    
 
Strain or 
plasmid 
Relevant properties Reference 
E. coli strains  
BL21 
E coli competent cell, fhuA2 [lon] ompT gal [dcm] 
ΔhsdS 
Invitrogen 
9196 
FanC-STa-BVDV fusion cloned to pET28a, NheI/EagI 
in BL21 competent cell 
This study  
9205 
FanC-STa-BVDV-LtA2-LtB, NheI/EagI in pBR322 in 
DH5α This study  
9300 
FanC-STa-BVDV-LtA2-LtB, HinIII/EagI in pBR322 in 
DH5α This study  
Plasmids   
p9196 FanC-STa-BVDV, NheI/EagI in pET28a   This study  
p9205 FanC-STa-BVDV-LtA2-LtB, NheI/EagI in pBR322 This study  
p9300 FanC-STa-BVDV-LtA2-LtB, HinIII/EagI in pBR322 This study  
p9073 FedF-LTA2-LTB, NheI/EagI in pBR322 Our lab 
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Supplement- figure-1:  
(A). Stock# p9300 the fanC-STa-BVD127-BVD153/LtA2-LtB in pBR322 HindII/ EagI 
@ DH5-α with FanC signal peptide, FanC promoter and FanC ribosomal binding site. (B) 
Stock# p9205,  fanC-STa-BVD127-BVD153/LtA2-LtB in pBR322 NheI/EagI @ DH5-α, 
Include pBR322 tetracycline gene & FanC signal peptide, and removed FanC promoter 
and FanC ribosomal binding site. (C). three dimension diagram of our expected fake 
holotoxin like structure in both constructs 9205 & 9300.    
C 
B 
A 
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(A) Anti-CT (1:3000) Western blotting, 12% PAGE gels, 
detect the LTB pentamer subunit from un boiled protein, 
samples of strain 9300& 9205.  
Supplement- figure-2:  
Detection fusion protein fanC-STa-BVDV-LTA2-LTB in pBR322. (B) Western 
blotting, anti-K99 polyclonal antibodies 1:1000. (C) Western blotting, anti-STa 
monoclonal antibodies 1:2500. (D) Western blotting, anti-BVDV NADL strain 
polyclonal antibodies 1:1000. No band was detected which means that the epitopes 
were not recognized and the protein is not completely assembled to the holotoxin 
structure. 
 
 
 
A 
B C D C B 
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ATG GGC AGC AGC CAT CNT CAT NNT CAT CAC AGC AGC GGC CTG GTG 
CCG CGC GGC AGC CAT ATG GCT AGC ACA CTC CTA GCT ATT ATC TTA 
GGT GGT ATG GCT TTT GCG ACT ACC AAT GCT TCT GCG AAT ACA GGT 
ACT ATT AAC TTC AAT GGC AAA ATA ACG AGT GCT ACT TGT ACA ATT 
GAG CCT GAG GTC AAT GGT AAT CGT ACA TCA ACT ATA GAT CTT GGG 
CAG GCT GCT ATT AGT GGT CAT GGC ACT GTA GTG GAT TTT AAA CTA 
AAA CCA GCG CCC GGC AGT AAT GAC TGC CTA GCG AAA ACA AAT GCT 
CGT ATT GAC TGG TCT AAC AAC ACA TTT TAC TGC TGT GAA CTT TGT TGT 
AAT TTT GCC TGT GCT GGA TGT GGA AAT ACT GCT GCT AAA GGA TAC 
CAT ATG ACT TTG CAT ACA AGA GCC TTG CCG ACC AGT GTG GTA TTC 
GCT AAT ATT AAT ACT TCA TTC ACT ACG GCT GAA TAC ACT CAC ACT TCT 
GCA ATT CAG TCA TTT AAC TAT TCA GCC CAG CTG GAC CAA CTA CTA 
TAC AAA GGG GGC TCT GGT GGA TAT AAA GCT GGC GTA TTT ACT ACT 
TCA GCA TCC TTC TTA GTC ACT TAT ATG TAA TAT TTA AAG TAT TTT ACA 
TTG CGG CCG CAC TCG AGC ACC ACC ACC ACC ACC ACT GAG ATC CGG 
CTG CTA ACA AAG CCC GAA AGG AAG CTG  
 
 
Supplement- DNA sequence-1:  
FanC-STa-E2 DNA sequence. Underlined are the three inserted epitopes pSTa12, BVDV 
E2 B cell and BVDV E2 T cell respectively. Bold gray background is the restriction sites 
NheI & EagI. 
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ATG TCC GCT TTC TGG TAT GCC GTG CGT ACT GCG GTG ATC AAC GCC 
GCC AGC GGT CGT CAG ACT GTC GAT GAA GCC CTG AAA GAC GCG CAG 
ACT AAT TCG AGC TCG AAC AAC AAC AAC AAT AAC AAT AAC AAC AAC 
CTC GGG ATC GAG GGA AGG ATT TCA CAT ATG CAC TTG GAT TGC AAA 
CCT GAA TTC TCG TAT GCC ATA GCA AAG GAC GAA AGA ATT GGT CAA 
CTG GGG GCT GAA GGC CTT ACC ACC ACT TGG AAG GAA TAC TCA CCT 
GGA ATG AAG CTG GAA GAC ACA ATG GTC ATT GCT TGG TGC GAA GAT 
GGG AAG TTA ATG TAC CTC CAA AGA TGC ACG AGA GAA ACC AGA TAT 
CTC GCA ATC TTG CAT ACA AGA GCC TTG CCG ACC AGT GTG GTA TTC 
AAA AAA CTC TTT GAT GGG CGA AAG CAA GAG GAT GTA GTC GAA ATG 
AAC GAC AAC TTT GAA TTT GGA CTC TGC CCA TGT GAT GCC AAA CCC 
ATA GTA AGA GGG AAG TTC AAT ACA ACG CTG CTG AAC GGA CCG GCC 
TTC CAG ATG GTA TGC CCC ATA GGA  TGG ACA GGG ACT GTA AGC TGT 
ACG TCA TTC AAT ATG GAC ACC TTA GCC ACA ACT GTG GTA CGG ACA 
TAT AGA AGG TCT AAA CCA TTC CCT CAT AGG CAA GGC TGT ATC ACC 
CAA AAG AAT CTG GGG GAG GAT CTC CAT AAC TGC ATC CTT GGA GGA 
AAT TGG ACT TGT GTG CCT GGA GAC CAA CTA CTA TAC AAA GGG GGC 
TCT ATT GAA TCT TGC AAG TGG TGT GGC TAT CAA TTT AAA GAG AGT 
GAG GGA CTA CCA CAC TAC CCC ATT GGC AAG TGT AAA TTG GAG AAC 
GAG ACT GGT TAC AGG CTA GTA GAC AGT ACC TCT TGC AAT AGA GAA 
GGT GTG GCC ATA GTA CCA CAA GGG ACA TTA AAG TGC AAG ATA GGA 
AAA ACA ACT GTA CAG GTC ATA GCT ATG GAT ACC AAA CTC GGA CCT 
ATG CCT  GGA TCC GAA TTC CCT GCA GGT AAT TAA 
 
Supplement- DNA sequence-2:  
BVDV-E2 DNA sequence. Underlined are the BVDV E2 B cell and BVDV E2 T cell 
respectively. Bold gray background is the restriction sites NdeI & BamHI. 
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ATG AAA TCT AAC AAT GCG CTC ATC GTC ATC CTC GGC ACC GTC ACC 
CTG GAT GCT GTA GGC ATA GGC TTG GTT ATG CCG GTA CTG CCG GGC 
CTC TTG CGG GAT ATC GTC CAT TCC GAC AGC ATC GCC AGT CAC TAT 
GGC GTG CTG CTA GCG ATG AAA AAA ACA CTC CTA GCT ATT ATC TTA 
GGT GGT ATG GCT TTT GCG ACT ACC AAT GCT TCT GCG AAT ACA GGT 
ACT ATT AAC TTC AAT GGC AAA ATA ACG AGT GCT ACT TGT ACA ATT 
GAG CCT GAG GTC AAT GGT AAT CGT ACA TCA ACT ATA GAT CTT GGG 
CAG GCT GCT ATT AGT GGT CAT GGC ACT GTA GTG GAT TTT AAA CTA 
AAA CCA GCG CCC GGC AGT AAT GAC TGC CTA GCG AAA ACA AAT GCT 
CGT ATT GAC TGG TCT AAC AAC ACA TTT TAC TGC TGT GAA CTT TGT TGT 
AAT TTT GCC TGT GCT GGA TGT GGA AAT ACT GCT GCT AAA GGA TAC 
CAT ATG ACT TTG CAT ACA AGA GCC TTG CCG ACC AGT GTG GTA TTC 
GCT AAT ATT AAT ACT TCA TTC ACT ACG GCT GAA TAC ACT CAC ACT TCT 
GCA ATT CAG TCA TTT AAC TAT TCA GCC CAG CTG GAC CAA CTA CTA 
TAC AAA GGG GGC TCT GGT GGA TAT AAA GCT GGC GTA TTT ACT ACT 
TCA GCA TCC TTC TTA GTC ACT TAT ATG  CAT CAT GCA CCA CAA GGT 
TGT GGA AAT TCA TCA AGA ACA ATC ACA GGT GAT ACT TGT AAT GAG 
GAG ACC CAG AAT CTG AGC ACA ATA TAT CTC AGG GAA TAT CAA TCA 
AAA GTT AAG AGG CAG ATA TTT TCA GAC TAT CAG TCA GAG GTT GAC 
ATA TAT AAC AGA ATT CGG GAT GAA TTA TGA ATG AAT AAA GTA AAA 
TGT TAT GTT TTA TTT ACG GCG TTA CTA TCC TCT CTA TAT GCA CAC GGA  
GCT CCC CAG ACT ATT ACA GAA CTA TGT TCG GAA TAT CGC AAC ACA 
CAA ATA TAT ACG ATA AAT GAC AAG ATA CTA TCA TAT ACG GAA TCG 
ATG GCA GGC AAA AGA GAA ATG GTT ATC ATT ACA TTT AAG AGC GGC 
GAA ACA TTT CAG GTC GAA GTC CCG GGC AGT CAA CAT ATA GAC TCC 
CAG AAA AAA GCC ATT GAA AGG ATG AAG GAC ACA TTA AGA ATC ACA 
TAT CTG ACC GAG ACC AAA ATT GAT AAA TTA TGT GTA TGG AAT AAT 
AAA ACC CCC AAT TCA ATT GCG GCA ATC AGT ATG GAA AAC TAG TAG 
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CGG CCG ACG CGC TGG GCT ACG TCT TGC TGG CGT TCG CGA CGC GAG 
GCT GGA TGG CCT TCC CCA TTA TGA TTC TTC 
  
 
 
 
Supplement- DNA sequence-3:  
Stock 9205 holotoxin like structure. FanC-STa-E2-LtA2-LtB includes fanC signal 
peptide (green). Underlined are the three inserted epitopes pSTa12, BVDV E2 B cell and 
BVDV E2 T cell respectively. Bold gray background is the restriction sites NheI & EagI. 
Blue is the LtA2 sequence, red is the LtB sequence. 
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T TCT CAT GTT TGA CAG CTT ATC ATC GAT AAG CTT TAG GGA ATG GCT 
ATG TTT TCT GGT GAT TCC ACG GAA CTA AAA AAT AAT ATC GAA CAA 
TGG AGA ATC TAG ATG AAA AAA ACA CTG CTA GCT ATT ATC TTA GGT 
GGT ATG GCT TTT GCG ACT ACC AAT GCT TCT GCG AAT ACA GGT ACT 
ATT AAC TTC AAT GGC AAA ATA ACG AGT GCT ACT TGT ACA ATT GAG 
CCT GAG GTC AAT GGT AAT CGT ACA TCA ACT ATA GAT CTT GGG CAG 
GCT GCT ATT AGT GGT CAT GGC ACT GTA GTG GAT TTT AAA CTA AAA 
CCA GCG CCC GGC AGT AAT GAC TGC CTA GCG AAA ACA AAT GCT CGT 
ATT GAC TGG TCT AAC AAC ACA TTT TAC TGC TGT GAA CTT TGT TGT AAT 
TTT GCC TGT GCT GGA TGT GGA AAT ACT GCT GCT AAA GGA TAC CAT 
ATG ACT TTG CAT ACA AGA GCC TTG CCG ACC AGT GTG GTA TTC GCT 
AAT ATT AAT ACT TCA TTC ACT ACG GCT GAA TAC ACT CAC ACT TCT 
GCA ATT CAG TCA TTT AAC TAT TCA GCC CAG CTG GAC CAA CTA CTA 
TAC AAA GGG GGC TCT GGT GGA TAT AAA GCT GGC GTA TTT ACT ACT 
TCA GCA TCC TTC TTA GTC ACT TAT ATG CAT CAT GCA CCA CAA GGT TGT 
GGA AAT TCA TCA AGA ACA ATC ACA GGT GAT ACT TGT AAT GAG GAG 
ACC CAG AAT CTG AGC ACA ATA TAT CTC AGG GAA TAT CAA TCA AAA 
GTT AAG AGG CAG ATA TTT TCA GAC TAT CAG TCA GAG GTT GAC ATA 
TAT AAC AGA ATT CGG GAT GAA TTA TGA ATG AAT AAA GTA AAA TGT 
TAT GTT TTA TTT ACG GCG TTA CTA TCC TCT CTA TAT GCA CAC GGA  GCT 
CCC CAG ACT ATT ACA GAA CTA TGT TCG GAA TAT CGC AAC ACA CAA 
ATA TAT ACG ATA AAT GAC AAG ATA CTA TCA TAT ACG GAA TCG ATG 
GCA GGC AAA AGA GAA ATG GTT ATC ATT ACA TTT AAG AGC GGC GAA 
ACA TTT CAG GTC GAA GTC CCG GGC AGT CAA CAT ATA GAC TCC CAG 
AAA AAA GCC ATT GAA AGG ATG AAG GAC ACA TTA AGA ATC ACA TAT 
CTG ACC GAG ACC AAA ATT GAT AAA TTA TGT GTA TGG AAT AAT AAA 
ACC CCC AAT TCA ATT GCG GCA ATC AGT ATG GAA AAC TAG TAGCGG 
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CCG ACG CGC TGG GCT ACG TCT TGC TGG CGT TCG CGA CGC GAG 
GCT GGA TGG CCT TCC CCA TTA TGA TTC TTC  
  
 
 
 
 
Supplement- DNA sequence-4:  
Stock 9300 holotoxin like structure. FanC-STa-E2-LtA2-LtB includes FanC promoter, 
ribosomal binding site and signal peptide (green). Underlined are the three inserted 
epitopes pSTa12, BVDV E2 B cell and BVDV E2 T cell respectively. Bold gray 
background is the restriction sites HindIII & EagI. Blue is the LtA2 sequence, red is the 
LtB sequence. 
 
 
